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ABSTRACT 
NARISA BORDEERAT: Quantification of Epoxide Metabolite Specific N-terminal 
Globin Adducts: A biomarker of Internal Dosimetry of 1,3-Butadiene Exposure  
and Metabolism  
(Under the direction of Dr. James A Swenberg) 
 
Butadiene (BD) carcinogenicity in rodents shows gender, species and 
concentration dependency, making the extrapolation of animal results to humans 
complex. BD is a multispecies multisite carcinogen, with mice being a much more 
sensitive species than rats. This is considered to be related to the metabolism of 
BD to its epoxy metabolites, 1,2-epoxy-3-butene (EB), 1,2;3,4-diepoxybutane 
(DEB) and 1,2-epoxy-butanediol (EB-diol). The mutagenic potency of individual 
epoxides varies up to 200-fold, with DEB being the most mutagenic metabolite. 
For accurate risk assessment it is important to elucidate species differences in 
the internal formation of the individual epoxides in order to assign the relative 
risks associated with their different mutagenic potencies. N-terminal globin 
adducts have been widely used for measurements of the formation of BD derived 
epoxides. In this study, the formation of each epoxide was evaluated in globin 
samples from both genders of mice and rats exposed to BD by inhalation for 10 
days. The numbers of globin adducts were then converted into EB dose 
equivalents. These were calculated on the basis of the combined internal dose 
(globin adducts) and the relative genotoxic potency of the respective epoxides 
inferred from the efficiency of inducing mutations at the Hprt locus.  
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Then, the multiplicative cancer risk model was applied to quantitatively 
estimate tumor incidence by using the EB dose equivalent and long-term cancer 
bioassay data. Based on the EB equivalent, higher exposures formed lower 
amounts per ppm BD. This indicates that metabolism of BD to epoxides is most 
effective at low exposures. The EB equivalent for mice was about 40-fold higher 
than that of rats at similar exposures. No gender differences were noted in globin 
adducts of mice or rats at all exposures. As such, EB dose equivalents provide 
quantitative data on biomarkers of exposure that can be extended to a scientific 
basis for BD risk assessment. 
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CHAPTER I 
 
LITERATURE REVIEW 
 
1.1 1,3-Butadiene: Overview 
1,3-butadiene (BD), CAS No. 106-99-0, is a colorless gas with a mild  
aromatic gasoline-like odor. The structure and molecular formulae (Figure 1.1) is 
that of an aliphatic compound and the relative molecular mass is 54.09 (1). BD is 
flammable at atmospheric concentrations and spontaneously forms a dimer at 
room temperature. It can also form explosive peroxides on contact with air, thus 
an inhibitor of peroxidation (4-t-butyl catechol) is added to commercial butadiene 
(2). 
1.1.1 Source of 1,3-Butadiene 
BD is mainly used in the production of plastics and synthetic rubber. It is  
manufactured  primarily  as a  co-product  of  ethylene production. This process 
accounts for over 95% of global butadiene production, with a demand of 9.3 
million metric tons worldwide in 2005 (3, 4).  The  major  uses  include  styrene-
butadiene  rubber  (30 – 35%), polybutadiene rubber (25%),  adiponitrile  (15%),  
and styrene-butadiene latex (10%) (1). BD  is  also  an  environmental  pollutant,  
present  in gasoline, motor vehicle exhaust, and cigarette smoke (4, 5, 6).  
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The U.S. EPA and IARC classified BD as a human carcinogen (class 1) 
based on animal studies in which laboratory rodents exposed to BD by inhalation 
and epidemiologic evidence suggesting that human BD industry workers have an 
increase incidence of leukemia (7–11). The most common exposure route for 
humans in the workplace is inhalation. According to the National Occupational 
Exposure survey (NIOSH, 1999), approximately 50,000 workers in the US were 
potentially exposed to BD (12). The United States Occupational Safety and 
Health Administration was adjusted permissible exposure limit (OSHA PEL) from 
1,000 ppm to 1 ppm for 8 h time-weighted average (TWA) in 1996, while the 
short-term exposure limit (OSHA STEL) was 15 ppm as a 15-min exposure (13). 
BD has been identified in cigarette smoke and delivery levels in the mainstream 
smoke of cigarettes ranges from 1.3 to 100 µg/cigarette (14, 15). Additionally, 
small amounts of BD are found in gasoline vapor, automobile exhaust, and fossil 
fuel incineration products. The U.S. EPA estimated that the mean concentration 
of BD in the ambient air of 19 U.S. cities in 1990 was 1.4 µg/m3 (16). Therefore, 
the general population, smokers and those nearby are exposed to this 
compound. 
 
1.1.2 Epidemiologic studies 
1.1.2.1 Mortality and Cancer studies 
Over the past 40 years, the relationship between exposure to butadiene  
and human health effects has been investigated in numerous studies. The most 
relevant investigations focused on working populations who were employed in 
butadiene monomer (BMD) and styrene-butadiene rubber (SBR) production. 
3 
 
 Three cohorts of BMD production workers in the US have been studied: at 
two Union Carbide plants in West Virginia (17), at a Texaco plant in Texas (18), 
and at Shell plants in Texas (19, 20).  The standard mortality ratio (SMR) for all 
cancers as a whole was 10% less than that for the US population rates. The first 
study focus on mortality among male workers who had been employed for at 
least six months at a 1,3-butadiene production facility between 1943 and 1979 
(21). The incidence of death from lymphosarcoma was increased 2-fold, but 
leukemia mortality rate was not evaluated. The SMR for lymphoma was 1.5 (21). 
These data showed no increase in adverse hematological parameters in relation 
to BD exposure.  
A follow up study in 1996 on the same group of workers, based on 
exposure concentration and duration showed that the leukemia SMR was 1.1 for 
workers employed more than 10 years and 1.8 for those employed less than 10 
years. The SMR for lymphosarcoma in short term exposure (<5 years) was 3.3-
fold higher than workers with 10 or more years of employment (22). Since there 
was no evidence on elevation of mortality rates with increased exposure duration, 
Divine and Hartman (1996) concluded that there was no casual relationship 
between leukemia occurrence and duration of employment in the BDM industry 
(22). 
 Two groups of SRB production workers have been studied. One was 
studied by the National Institute of Occupational Safety and Health (NIOSH) in a 
two-facility complex in Ohio (23–25), and the other comprised of workers from 
eight facilities in the USA and Canada who were studied by the Johns Hopkins 
University’s researchers (26–28). Subsequently, researchers from the University 
of Alabama at Birmingham (UAB) (29) studied the same facility complex 
4 
 
investigated by NIOSH in addition to the seven facilities studied by the Johns 
Hopkins University. The most recent updated results published from these 
groups have been reviewed (30–34). The epidemiology data indicate that the 
worker mortality rates from all cancers as a whole were equal or less than the US 
average; however, mortality rates from leukemia were increased in the male SRB 
workers populations (31, 35). The UAB investigators also conducted analyses 
using the new World Health Organization (WHO) disease classification scheme 
for leukemias and lymphomas. Based on this WHO classification, chronic 
myelocytic leukemia (CML) was most strongly associated with peak exposures, 
while chronic lymphocytic leukemia (CLL) showed an opposite pattern, i.e., a 
stronger association with cumulative versus peak exposures to BD (31, 32). 
Additionally, the UAB findings represent the effect of BD exposure in the 
presence of styrene and other SRB chemicals (e.g. dimethyldithiocarbamate, 
DMDTC). Since there was a high correlation between BD and styrene exposure 
in the cohort, a possible role for styrene as a co-exposure factor could not be rule 
out. 
 Mortality rate for female workers employed in the SRB industry from 1991 
to 1994 are currently studied (36). However, results were unavailable due to 
delays in accessing mortality follow-up information. The UAB investigators 
anticipate approximately 30-35 lymphohematopoietic cancer deaths among 5,000 
female SRB workers; this study will contribute significant new information once 
completed. 
 In conclusion, epidemiological studies for both SRM and BDM industries 
report an overall deficit in cancer mortality in BD-exposed workers. An elevated 
incidence of leukemia mortality was observed for long-term workers routinely 
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exposed to BD in SBR industries (29, 30, 37). On the other hand, no increase in 
leukemia deaths and no correlation between leukemia incidence rate and BD 
exposure were observed in BDM cohort (22). This finding is inconsistent between 
the results for workers employed in SRB and BDM industries. This may reflect 
generally lower exposures in the BDM or the presence of the co-exposure to BD 
and other chemicals (styrene and DMDTC) in SRB industries. Since the UAB 
data set provides the largest and most comprehensive consistent data set 
available on occupationally BD exposed workers, the weight of evidence 
indicates that BD is weakly leukemogenic in humans with long term exposure 
(30-40 years) (38).  
1.1.2.2 Molecular studies 
 While studies of the relationships between BD exposure and cancer in 
humans have given various results, a number of studies have been found an 
association with leukemia and lymphomas. All increases in leukemia deaths have 
been confined to the sub-group classified as CML. Molecular epidemiological 
studies in humans can provide information analogous to cancer data that can be 
derived from animal studies, using biomarkers to assess metabolism and 
measure internal doses of BD metabolites to examine potential pre-neoplastic 
effects and identify issues related to increased susceptibility to BD. 
 Molecular epidemiology studies on 41 SRB workers in China exposed to 
BD demonstrated that exposed workers had greater amounts of hemoglobin (Hb) 
adducts and white blood cell counts when exposed to 2 ppm of BD (6-h TWA). 
However, the levels of hemoglobin N-(2,3,4-trihydroxybutyl) valine (THB-Val) 
adducts were not associated with genotoxic effects evaluated as sister chromatic 
exchanges, glycophorin A or Hprt mutations. The study suggests that neither 
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short-term, nor long-term exposures to BD in these workers induced specific 
genotoxic effects at the chromosomal or gene levels (39–42).  
 A large-scale international molecular epidemiological study of BD exposed 
Czech workers was initiated in 1998 and reported in 2003 (43–45). Albertini et al. 
reported a clear no-observed-adverse-effect level (NOAEL) for biomarkers of 
effect; Hprt mutations and chromosome aberrations, at mean BD exposure 
concentration of 0.8 ppm. This study utilized a comprehensive series of 
biomarker responses, including urinary metabolites and Hb adducts, Hprt 
mutations, sister-chromatid exchange frequencies and chromosomal aberrations. 
Both urine metabolites and Hb adduct concentrations proved to be excellent 
biomarkers of exposure. 
 A second study of Czech workers was conducted at the same facility to 
compare biomarker responses in female and male employees (46, 47). Mean BD 
exposure concentrations were lower in this study than in the first study, being 
0.18 ppm and 0.37 ppm for females and males, respectively. There were no BD-
associated elevation above background for Hprt mutations or chromosome 
aberration frequencies in either sex. Similarly, there was no difference between 
genders in the pattern of BD detoxication, as indicated by urinary M2/(M1 + M2) 
ratios levels. Females appeared to absorb or metabolize less BD than males per 
unit of exposure. Workers also were genotyped for polymorphisms in several 
metabolic genes in both Czech studies. Although some genotype-associated 
differences in metabolic patterns were observed, there were no such differences 
for biomarkers of effect such as Hprt mutations or chromosome aberrations in 
either study. 
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1.1.3 Metabolism of 1,3-butadiene 
BD is metabolically activated by cytochrome P450 monooxygenases  
(P450) forming reactive electrophiles. As shown in Figure 1.2, BD is initially 
oxidized to the 1,2-epoxybutene (EB), a reactive metabolite mediated primarily by 
cytochrome P450 isozyme CYP2E1, although other isozymes such as CYP2A6 
have also been shown to be involved (48). Further P450 oxidation of EB 
produces 1,2:3,4-diepoxybutane (DEB). Detoxification of EB proceeds by 
conjugation with glutathione (GSH) (mediated by glutathione-S-transferase, GST) 
or by hydrolysis (mediated by epoxide hydrolase, EH), the latter producing the 
1,2-dihydroxy-3-butene (butanediol, B-diol) metabolite. Both DEB and B-diol 
undergo further conversions in vivo, DEB by EH hydrolysis and B-diol by 
CYP2E1 oxidation to produce the 3,4-epoxy-1,2-butanediol (EB-diol). B-diol can 
also be metabolized by alcoholdehydrogenase (ADH) and CYP2E1 to form 
hydroxymethylvinylketone (HMVK) (38). 
 All three reactive epoxides of BD (EB, DEB, and EB-diol) can react with 
nucleophilic sites in biomolecules, including DNA and proteins. The DNA adducts 
can result in one or more genotoxic events relevant to the carcinogenic mode of 
action (MOA) for BD (49). DEB, while not the major metabolite formed, is a 
bifunctional alkylating agent. It is capable of binding to two cellular 
macromolecules [e.g., DNA-protein crosslinks; (50)] or to the same molecule 
twice [e.g., DNA-DNA crosslinks; (51, 52)]. DEB is considered the most potent 
carcinogenic metabolite of BD and is by far the most mutagenic metabolite of BD 
(53, 54). DEB is 50 times more mutagenic than EB and 100 times more 
mutagenic than EB-diol (53).  
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 The major detoxication enzyme for epoxide metabolites of BD are EH and 
GST conjugation. Direct GST-mediated conjugation of EB with GSH leads to 1-
hydroxy-2-(N-acetylcysteinyl)-3-butene as a racemic mixture with 1-(N-
acetylcysteinyl)-2-hydroxy-3-butene known as M2 , a urinary metabolite and a 
biomarker for this pathway. The GST-mediated conjugation of HMVK with GSH 
leads to the production of 1,2-dihydroxy-4-(N-acetylcysteinyl)-butane, known as 
M1, a second urinary metabolite. The GSH conjugation product of DEB forms 
1,3,4-trihydroxy-2-(N-acetylcysteinyl)-butane, known as the  M3. M1 is a 
biomarker of the hydrolytic pathway because EH-mediated hydrolysis of EB is the 
initial step, followed by reaction with alcohol dehydrogenase and cytochrome 
P450 to form HMVK. The ratio M1/(M1 + M2) in urine provides an estimate of the 
relative importance of hydrolysis versus conjugation in the detoxication of EB (55, 
56). 
 
1.1.4 Physiologically based pharmacokinetic (PBPK) model 
 PBPK models can be applied as a tool to use in vitro and in vivo rodent 
and in vitro human data to predict the dosimetry of BD in humans. The goal of 
PBPK models is to aid extrapolation of rodent results to humans to understand 
species differences in metabolism and pharmacokinetics. PBPK models of BD 
and its metabolites have been developed at the Chemical Industry Institute of 
Toxicology (CIIT) (57) and other laboratories (58–68).  
 The CIIT PBPK model has used rates of BD and EB metabolism 
determined in vitro (69). The in vitro metabolic rates were adapted to account for 
metabolism by the entire liver rather than just a subcellular fraction. This model 
demonstrated that in vitro metabolism parameters could predict in vivo 
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disposition in animals. It suggested that in vitro parameters derived from human 
tissue might also be predictive of the disposition of BD in humans (70). 
Furthermore, the Medinsky model included metabolism of BD in the lung. To gain 
insight into the potential importance of lung metabolism, several different models 
simultaneously were conducted and concluded that lung metabolism may be 
important in defining lung tissue (57). 
 Elfarra et al. (1996) described studies in which the isozyme specificity of 
the BD to EB and the EB to DEB reactions were determined with human 
cytochrome P450s. Human myeloperoxidase was observed to catalyze formation 
of EB from BD, but not DEB from EB (58). 
 Kohn and Melnick et al. (1996) discussed the effects of the structure of a 
PBPK model for BD and EB and how different descriptions of the compartments, 
flows, and kinetic constants can affect the predictions. They concluded that 
reliable physiological and kinetic data must be used to build the model before it 
can be useful for interspecies extrapolation and risk assessment (59). In 2001, 
Kohn and Melnick et al. revised their model to include a transient complex 
between cytochrome P450 and microsomal EH (60). The model was further 
enhanced by the addition of equations for the production and detoxication of EB-
diol in the liver, lungs, and kidneys in mice and rats. The results demonstrated 
that the model predicted accumulation of EB-diol in animals exposed to BD, 
which is consistent with observations that most of the DNA adducts arise from 
EB-diol. 
 Bond et al. (1996) discussed data used to set parameters in a PBPK 
model for BD and EB, as well as data being developed on DEB that could be 
used in PBPK models (61). In vivo studies of epoxide disposition after BD 
10 
 
exposure were fit a PBPK model to show the importance of reliable in vitro data 
for accurate predictions, and the role of lung metabolism in mice. 
 Csanady et al. (1996) developed a PBPK model to describe disposition 
and metabolism of BD and EB in rats, mice and humans (62). In addition, DEB 
disposition and metabolism was also described in mice. The model described the 
formation of EB and DEB, intrahepatocellular first-pass hydrolysis of EB, 
conjugation of EB with GSH and GSH turnover in the liver. The authors reported 
that species differences in EB dosimetry were not sufficiently large to explain the 
observed species differences in carcinogenic potency for BD, suggesting that 
additional factors are involved. 
 Johnson and Filser et al. (1996, 2010) developed a PBPK model for BD 
and its metabolites in mice, rats, and humans (63–65). The model includes 
compartments for lung, liver, fat, and a vessel-rich group. It incorporated three 
important features: (1) reduce alveolar ventilation; (2) intrahepatic first-pass 
hydrolysis of EB; and (3) a two substrate Michaelis-Menten kinetic description of 
EB conjugation with GSH. The authors concluded that relatively small differences 
in EB between mice and rats as internal EB doses could only partly explain the 
marked species difference in cancer response between mice and rats exposed to 
BD. 
 Sweeney et al. (1996, 1997, 2001) demonstrated in vivo and in vitro BD 
metabolism data in laboratory animals that were integrated into a PBPK model in 
rats with flow- and diffusion- limited compartments (66, 67). The model described 
experiments from closed chamber inhalation and nose-only flow through 
inhalation exposures. Blood concentrations of BD were accurately predicted for 
mice and rats exposed by inhalation to constant concentrations of BD. A 
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preliminary human model was developed that accurately predicted published 
data on exhaled breath BD concentrations in a human volunteers exposed to BD 
inhalation (68). Human blood DEB was found to be sensitive to rates of 
epoxidation of EB to DEB and hydrolysis of EB and DEB. 
 In conclusion, the PBPK models are proving to be very useful for testing, 
and given their quantitative nature, could be a key tool in risk assessment of BD. 
PBPK models can be used to address questions of extrapolation of critical 
metabolites in tissues from high to low exposure concentrations. These models 
will also be useful in resolving conflicting observations about interspecies 
differences in metabolism. 
 
1.2 BD toxicity studies 
1.2.1 Acute toxicity  
 Acute toxicity effects have been observed at high BD exposure 
concentrations. The median lethal concentration (LC50) in rats for a 4-h exposure 
was 129,000 ppm or 12.9% and in mice for a 2-h exposure was 123,000 ppm or 
12.3% (71). Early toxicology studies indicated that BD caused irritation to mucous 
membranes, skin, and eyes, or narcosis only at high BD concentrations (8,000 
ppm). Human volunteers exposed to 2,000, 4,000, or 8,000 ppm BD for 6 to 8 h 
experienced minor irritation to eyes and difficulty in visual focusing (72). In 
addition acute inhalation of 2,000 to 8,000 ppm, BD can cause irritation of upper 
respiratory tract. Coughing and bronchospasm can occur, especially in 
susceptible individuals, such as persons with asthma. Bradycardia and 
hypotension secondary to CNS depression is possible with exposure to very high 
concentrations (150,000-250,000 ppm) of BD (73). 
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1.2.2 Chronic toxicity 
 BD has been considered to have a low and noncumulative toxicity in 
animals and human. Melnick et al. (1990) demonstrated nonneoplastic lesions 
associated with chronic inhalation of BD (74). B6C3F1 mice exposed to 6.25 – 
625 ppm BD for 40–65 weeks exhibited epithelial hyperplasia of the forestomach, 
endothelial hyperplasia of the heart, alveolar epithelial hyperplasia, hepatocellular 
necrosis, testicular atrophy, ovarian atrophy, and toxic lesions in nasal tissues 
(chronic inflammation, fibrosis, cartilaginous metaplasia, and atrophy of the 
olfactory epithelium) (74). Testicular atrophy was induced at 625 ppm BD, and 
ovarian atrophy was observed at concentration as low as 6.25 ppm. 
 In a study of hematological parameters in mice exposed to BD at 62.5–
625 ppm, decrease in RBC count, Hb concentration, and packed red cell 
volumes were found (75–77). These changes were not accompanied by 
increases in reticulocyte counts or in the frequency of polychromatic erythrocytes 
in peripheral blood, and may indicate a poor regenerative response in the bone 
marrow to reduced levels of circulating erythrocytes. 
 Thurmond and associates (1986) observed significant extramedullary 
hematopoiesis and erythroid hyperplasia in spleens of male B6C3F1 mice 
exposed to 1,250 ppm BD for 24 weeks (78). One explanation of these results is 
that exposure to BD caused suppression of hematopoiesis in the bone marrow, 
and that young large red cells were released into the blood from extramedullary 
sites, such as the spleen. These findings establish the bone marrow as a target 
of BD toxicity in mice (78).  No BD exposure-related gross or microscopic 
changes or effects on growth, survival, hematologic and blood biochemical 
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parameters, urinary measurements, or neuromuscular functions were observed 
in male and female Sprague-Dawley (SD) rats exposed to BD at concentrations 
ranging from 1,000 to 8,000 ppm (6 hours/day, 5 days/week for 13 weeks) (79). 
 
1.2.3 Carcinogenicity studies in laboratory animals 
 The carcinogenicity of inhaled BD was studied in B6C3F1 mice by the 
National Toxicology Program (NTP) and in SD rats by the International Institute 
of Synthetic Rubber Producers (IISRP) (Table 1.1). The NTP studies 
demonstrated that BD is a potent multi-site carcinogen. In the first NTP study, 
male and female mice were exposed 6 h/day, 5 days/week, to air containing 0, 
625, or 1,250 pm BD (80, 81). This study was terminated after 60 to 61 weeks 
because of reduced survival due to malignant neoplasms at multiple sites. 
Malignant lymphomas, observed as early as week 20, were the major cause of 
early deaths in both sexes. In addition, there was early induction and increased 
incidences of hemangiosarcomas of the heart and neoplasms of the lung and 
forestomach in males and females, and of the mammary gland, ovary, and liver 
in females. The high incidence of hemangiosarcomas of the heart was a 
particularly unusual finding because this neoplasm is extremely uncommon in 
B6C3F1 mice. 
 In an expanded NTP study, male and female mice were exposed to 0, 
6.25, 20, 62.5, 200, or 625 ppm BD for up to 2 years (82). Consistently, 
lymphomas were the major cause of early deaths for both sexes exposed to 625 
ppm. The incidence of lymphomas was also increased in females exposed to 200 
ppm. Hemangiosarcomas of the heart were observed at concentrations as low as 
20 ppm in males and 62.5 ppm in females. Incidences of lung neoplasms in 
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female mice were increased at all concentrations, including the 6.25 ppm 
exposure. The harderian gland was also identified as a site of BD-induced 
neoplasia. 
 Stop-exposure experiments after BD exposure at one year were also 
conducted in mice to assess the relationship between concentration and duration 
of exposures on BD-induced carcinogenicity (83). These studies demonstrated 
that tumors were induced at multiple organ sites even only 13 weeks of exposure 
to 625 ppm BD, and that at comparable total exposures, the incidence of 
lymphoma was greater with exposure to a higher concentration of BD for a 
shorter time (e.g. 625 ppm for 26 weeks) compared with exposure to a lower 
concentration for a longer time (e.g. 312 ppm for 52 weeks). Thus, for the 
development of lymphomas, the concentration of BD is a greater contributing 
factor than is the duration of exposure. 
 In the IISRP study, rats of each sex was exposed to 0, 1,000 or 8,000 ppm 
BD 6 h/day, 5 days/week, for 2 years (10). Results from the study were also 
reported later by the same author in 1993 (84). Minor clinical effects, including 
excessive eye and nose secretions plus slight ataxia, were observed between 2 
and 5 months in rats exposed to 8,000 ppm. Alterations in organ weight were 
also observed in this high exposure group. Following exposures up to 2 years, 
BD was carcinogenic at multiple organ sites, as evidenced by increased 
incidences or dose-response trends for neoplasms of the pancreas and testis in 
males, and of the mammary gland, thyroid gland, uterus, and zymbal gland in 
females. In addition, the average number of mammary gland fibroadenomas was 
increased in both exposure groups compared to control. The increased number 
of uncommon glial cell tumors of the brain in exposed male rats, though not 
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statistically significant, may also have been related to BD exposure (85). These 
studies reveal that the carcinogenic effects of BD differ markedly between rats 
and mice with respect to sites of tumor induction.   
 
1.2.4 Species and gender differences in BD metabolism 
 Carcinogenicity studies in animals have clearly shown differences in 
species susceptibility to BD induced tumor formation. For example, in chronic BD 
exposure studies, mice developed tumors at 6.25 ppm BD, while rats developed 
tumors at exposures of 1,000 ppm BD (9, 10). These notable interspecies 
differences in susceptibility to BD-induced cancer are believed to be due to 
differences in the extent of formation of DEB in rat and mouse tissues. The rate 
of P450 oxidation of BD to EB and EB to DEB is roughly 3.5-fold faster in mice 
compared to rats (85). Moreover, the rate of EH hydrolysis of EB to B-diol is 2.7 
fold faster in rats compared to mice (85).  Furthermore, microsome studies of BD 
metabolism in mouse, rat, and human microsomes have shown that mice indeed 
form greater levels of DEB than both rat and human microsomes (85). This is due 
to a greater rate of oxidation of BD to EB and EB to DEB in mouse tissues, as 
well as a slower rate of hydrolysis of EB and DEB in mice as compared to rat and 
human microsomes (85). In contrast, rat cytochrome P450 2E1 monooxygenase, 
the major isoform of mixed function monooxygenase responsible for BD 
metabolism to EB and DEB, can form covalent binding with Tyr and His residues 
within its active site (86). This could partially explain why BD-exposed rats form 
more EB but less DEB than mice and are less susceptible to BD induced cancer.  
 Multiple BD inhalation studies have revealed gender differences in 
metabolism and carcinogenicity. Female mice developed lung and liver tumors 
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after exposure to 6.25 ppm BD, whereas male mice did not form tumors until 
exposure to 62.5 ppm BD or higher (38). In another study, female rats exposed to 
a single 6-h exposure of 62.5 ppm BD had 4.75-fold higher blood concentrations 
of DEB than did male rats that received the same exposure (87). Similarly, 
female mice had greater DEB concentrations in blood, femur, lung and fat tissue 
as compared to male mice receiving the same BD exposure (87).  
 A possible cause of the observed gender differences in BD metabolism is 
differences in enzymes involved in the metabolism, P450 monooxygenases and 
EH. P450s are responsible for the production of DEB as it oxidized BD to EB, 
and EB to DEB. There is evidence that some isoforms of cytochrome P450
 
(CYP2C12) are expressed only in females, while others (CYP2C6 and CYP2A1) 
are expressed in both sexes, but not more abundant in females (88). In addition, 
an increased level of expression of BD-oxidizing enzymes in females as 
compared to males may be responsible for the observed differences in toxicity of 
BD between the sexes (89).  
 Another key enzyme involved in the metabolism of BD is EH, which is 
involved in detoxication of BD epoxides to the corresponding diols. In general, 
testosterone has been noted to stimulate cytosolic EH expression leading to 
overall activity of EH in male mice than in female (90, 91). In contrast, female 
mice had greater activity of cytochrome P450 monooxygenases, resulting in 
increased formation and decreased hydrolysis of reactive BD metabolites, 
specifically DEB. Similarly, results were presented for BD exposed rats, blood of 
female animals contained higher concentrations of DEB as compared to males 
(89).  
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However, a recent study of hemoglobin adducts showed no significant 
gender differences at the exposure concentrations studied (151). In addition, 
there were no gender differences in the amount of DNA monoadducts indicate 
that there is no difference in BD metabolism in rodents at multiple exposure 
concentrations and durations. This comprehensive data set strongly suggests 
that a deficiency in DNA cross-link repair in females is the most plausible 
hypothesis for the gender differences in mutagenic and carcinogenic 
susceptibility. 
 
1.3 Genotoxiciy and mutagenicity studies 
 BD has been tested for genotoxicity in a number of in vitro and in vivo 
studies. Furthermore, molecular and genetic toxicity of BD and its metabolites 
have been extensively evaluated in wide variety of test systems including 
bacterial cells, yeasts, Drosophilia, mammalian cell and rodents (92–97). In order 
to summarize the huge amount of genotoxicity information, this review is 
organized according to the mutational endpoints in in vivo and in vitro test 
systems. 
 
1.3.1 In vitro studies of mutagenicity of BD and its metabolites 
 BD metabolites have been studied for mutagenicity in a variety of test 
systems. Positive results have been found in the reverse mutation assay in 
Salmonella typhimurium, the first test organisms employed to test parent BD and 
its metabolites (98–107). On the basis of these data, BD appears to require 
metabolic activation to produce genotoxicity. DEB induced gene mutations, 
mitotic recombination, and gene conversions in eukaryotic microorganism (108–
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112). Mammalian cells in culture have been extensively employed in studies of 
the mutagenicity of BD’s metabolites. Each of the major metabolites has been 
shown to induce gene mutations in endogenous genes (Hprt and TK) and 
intrans-genes (lac I and c II) using different cell systems, i.e., mouse lymphoma, 
fibroblasts, CHO cells, TK6 human fibroblasts, mouse and rat transgenic 
fibroblasts (113–116). It is noteworthy that EB primarily induces point mutations 
(A:T to T:A transversions) and small deletions, whereas DEB, a bifunctional 
alkylating agent, results in large deletions (113, 114). The relative mutagenic 
potencies of the three major electrophillic metabolites of BD have been 
determined in several studies of gene mutations employing both endogenous and 
transgenes as targets. The findings have always shown these potencies to be 
DEB >> EB > EB-diol (117). In mutagenic studies using endogenous gene 
targets in cultured human lymphoblast TK6 cells and the cII transgene in mouse 
fibroblasts, DEB was approximately 50-fold more potent than EB and 100-fold 
more potent than EB-diol (57, 117–119). 
 Chromosome-level mutations were studied both as chromosome 
aberrations and as micronuclei (MN) in several cell types; including rat embryo 
fibroblasts, rat hepatocytes, and human peripheral blood lymphocytes (PBLs) 
(120–125). Most studies concentrated on DEB, perhaps because it is the most 
efficient of the metabolites for inducing chromosome-level changes. 
 The studies exploring the effect of DNA repair were revealed that repair 
was usually effective in correcting EB lesions before they could produce 
chromosome aberrations (121, 123–124). DEB induced chromosome–level 
mutations (aberrations and MN) were shown to be influenced by the Fanconi 
anemia gene, where mutations confer sensitivity in both homozygotes and 
19 
 
heterozygotes (125–129).  When BD metabolites were evaluated for relative 
potencies in inducing micronuclei in mouse and rat transgenic fibroblasts, the 
relative order was again DEB >> EB > EB-diol, with ratios being approximately 
the same as for introducing gene mutations (119). In other studies, DEB was also 
shown to induce heritable (stable) translocations in human lymphoblastoid cells 
(130–131).  
 In summary, BD metabolites have induced gene mutations in different 
prokaryotic assay systems. BD itself has been positive only in the presence of 
external metabolic activation. DEB has always been the most potent mutagen of 
the BD metabolites. 
 
1.3.2 In vivo mutagenicity of BD and its metabolites 
 Studies of mutations arising in vivo at either the gene- or chromosome-
level provide a mode of action for the carcinogenic potential of BD. Hprt 
mutations in splenic lymphocytes were studied in mice exposed to 625 ppm BD 
by inhalation for 10 days (6 h/day, 5 days/week for 2 weeks), or  total doses of 
180, 240, and 500 mg/kg of EB, or to total doses of 21, 28, and 42 mg/kg DEB by 
intraperitoneal injections (i.p.) (53, 117). Induced mutations, as indicated by 
increased Hprt mutant frequencies (MFs) above background, were observed at 
all doses of BD and its metabolites in young animals, who were 7 to 10 days of 
age at the initial of exposures.  
 Analysis of mutational spectra can detect only “point mutations” in exon 3 
and not deletions encompassing larger portions of the gene. They showed an 
increase in +1 frameshift mutations for all epoxides metabolites and transversion 
and transitions involving both GC and AT base pair for EB and DEB, but was 
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limited to AT base pairs for BD. In contrast to EB and BD, the yield of mutations 
with DEB showed the induction of deletions. 
 In a later study, Tates et al. (1994, 1998) used older animals (11 – 12 
weeks of age) that were exposed to BD by inhalation (200, 500, and 1,300 ppm 
for 6 hours/day for 5 days) or to EB (33 or 100 mg/kg for each of three i.p. 
injections), or to DEB (various doses by i.p. injection) did not give such positive 
results in Hprt MFs in splenic lymphocytes for BD and DEB at any dose tested 
(132). However, EB gave a significant increase in MF only at the highest dose 
(132, 133). 
 Later, a series of studies then were applied a modified assay system that 
included larger numbers of young (4–5 weeks) animals. They were measuring 
mutations at optimum expression times and defining BD’s relative mutagenicity in 
mice and rats. These studies identified the roles of EB and DEB for BD’s 
mutagenicity at different doses and better established the BD induced Hprt 
molecular mutation spectrum (134–143). When Hprt MFs were studied at multiple 
times postexposure to BD by inhalation at 1,250 ppm 6 h/day, 5 days/week for 1 
or 2 weeks, the expression times for mutation manifestation in thymic 
lymphocytes were 2 or 3 weeks postexposure for mice and rats, respectively, and 
for mutation manifestation in splenic lymphocytes were 5 or 4 weeks 
postexposure, for mice and rats, respectively. 
 In summary, there is a clear evidence that BD induces mutagenic effects 
in in vivo test systems primarily through its reactive metabolites, EB and DEB. In 
vivo studies indicate that EB primarily induces point mutations (A:T to T:A 
transversion) and small deletions, whereas DEB, also results in large deletions. 
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1.3.3 Species and gender differences in BD mutagenicity 
 Several studies of mutations suggest that BD, a genotoxic agent, induces 
cancer by a mutagenic mode of action (MOA). Such events show not only that 
BD epoxides reach critical targets in vivo and that they produce the kinds of 
irreversible genetic effects that alter genetic information. Because of their 
importance in an overall mutagenic evaluation of BD that incorporates 
metabolism in the different species and genders, the reviews in this section are 
discussed in greater detail. 
 BD’s relative mutagenic potency in mice and rats were explored by 
exposing both species by inhalation at 20, 62.5, or 625 ppm on the same daily 
schedule for 2 or 4 weeks (134, 136). In addition, they exposed additional group 
of mice to 3 ppm BD for 2 weeks. (135, 138, 142). Mice showed a significant 
increase in Hprt MFs in splenic lymphocytes at the lowest exposure tested, i.e., 3 
ppm, whereas a significant increase in MFs in rat splenic lymphocytes was 
observed only at 62.5 ppm. It is noteworthy that mice exposed to 3 ppm for 2 
weeks and rats exposed to 62.5 ppm for this same duration were subsequently 
shown to have approximately the same number of DEB globin adducts in blood, 
as determined by the DEB-specific, pyr-Val, hemoglobin adduct assay (86). This 
suggests strongly that the important BD metabolite for inducing gene mutations 
at low BD exposures is DEB. These comparative studies also showed that 
gender, as well as species, influences the mutagenic response to BD, with the 
order being female mice > male mice > female rats > male rats. 
Analyses of dose response curves for Hprt mutations in the two species 
showed that the curve of mice was supralinear, whereas in rats curve was 
shallow but linear. This influences the determination of relative mutagenic 
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potencies of BD in the two species, which will differ at different exposure 
concentrations. At 625 ppm this potency was estimated to be 9-fold greater in 
mice than in rats, compared to a 5-fold difference at 1,250 ppm (135, 142). 
The relative roles of racemic EB and DEB in determining BD’s 
mutagenicity at different exposures in mice and rats were specifically investigated 
by administering EB or DEB by inhalation for 6 h/day, 5 days/week for 4 weeks 
(136). It was observed that the mutagenic potency of racemic EB administered by 
inhalation in mice was much lower than the mutagenic potency of BD at the 
exposure levels that would give the corresponding EB blood levels, indicating 
that EB is not the major mutagenic metabolite of BD in mice at either 62.5 or 625 
ppm. In contrast, the mutagenic potency of DEB administered by inhalation at 
both 2 and 4 ppm exposure levels to mice was approximately equivalent to BD’s 
mutagenic potency at an exposure level of 62.5 ppm. DEB was the major 
contributor to BD’s mutagenicity in mice at exposure levels of 62.5 and below. 
Rats showed a different picture in the study. Exposure to racemic EB did not 
induced significant mutation, whereas DEB at both exposures showed greater 
mutagenicity than in mice. This illustrates the potent mutagenicity of DEB in rats 
but also that rats do not produce high levels of DEB from BD at 62.5 ppm, as that 
level of BD exposure was only minimally mutagenic in rats (135–136, 142).  
A recent study provided important data on the mutagenic potency of BD at 
low exposure (3 ppm) and the metabolites B-diol in different genders and species 
of rodents (143). The study included a series of experiments in which male and 
female rats and mice were exposed BD or its metabolites DEB and B-diol via 
inhalation. These studies confirmed and extended earlier observations that 
female rodents are more susceptible than male rodents to BD exposure. In 
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addition, mice are more susceptible than rats to inhaled BD. The investigators 
demonstrate that in both species the contribution of the metabolites B-diol and 
EB-diol to mutagenicity induced by BD exposure is most prominent at high BD 
concentrations, whereas the metabolite DEB is probably more important at lower 
concentrations. Therefore, the difference in sensitivity to BD between species 
and genders in all mutagenicity tests points towards differences in production and 
detoxication of DEB and EB-diol. 
 
1.4 1,3-Butadiene biomarkers 
 Over the past 10 years, several protein and DNA adducts of BD reactive 
metabolites have been measured as biomarkers of BD exposure and effect (73, 
144). Quantification of biomarkers has been performed by various methods. The 
studies are briefly reviewed below. 
 
1.4.1 Hemoglobin adducts 
 Hemoglobin (Hb) adducts have been extensively used as biomarkers for 
evaluating the “internal dose” of various chemicals (145–151). They can provide 
quantitative dose estimates in blood in experimental animals and in 
occupationally exposed humans. N-terminal valine adducts of Hb are recognized 
as good surrogate markers to study carcinogen metabolism across species, 
since they offer many advantages. Blood samples are easier to obtain than 
tissues, and globin adducts accumulate over the life-span of erythrocytes, which 
is about 45, 63, and 120 days for mice, rats, and humans, respectively. Since 
they represent cumulative exposure prior to sampling, the time of sample 
collection is less critical. In addition, the N-terminal valine is freely accessible to 
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alkylating agents in all species, allowing interspecies comparisons relative to 
metabolism and cancer risk. Therefore, N-terminal valine adducts are valuable 
biomarkers to study the internal formation of the reactive metabolites of BD-
derived epoxides (86, 151–152). 
 For internal dose measurements of epoxides, their adducts to Hb can be 
used as dosimeters (152). All of the epoxide metabolites of BD react with N-
terminal valine in Hb, mainly by nucleophillic attack on the least hindered carbon 
(152). They form three different adducts: N-(2-hydroxy-3-butenyl)-valine (HB-
Val); N, N-(2, 3-dihydroxy-1, 4-butadiyl)-valine (pyr-Val), and N-(2, 3, 4-
trihydroxubutyl)-valine (THB-Val), originating from EB, DEB, and EB-diol, 
respectively (Figure 1.3).  
 
1.4.1.1 Quantitation of BD derived N-terminal valine Hb adducts 
 In the last several years, Hb adducts from EB, HB-Val, were initially 
analyzed by the N-alkyl Edman method (148) in rats treated with different 
concentrations of BD. The HB-Val adducts were shown to be stable and they 
increased linearly with exposure concentration. In following studies both 
regioisomers of HB-Val adduct were quantified in rats and mice exposed to 
different concentrations of BD (153–155). 
 THB-Val mainly forms from the reaction of EB-diol with the N-terminal 
valine of globin. This adduct has been analyzed in both laboratory animals and 
humans exposed to BD in an occupational setting. THB-Val was quantified by 
using the N-alkyl Edman method with modification in the extraction of formed 
pentafluorophenylthiohydantoin (PFPTH) according to Perez et al. (1997) (156). 
In rats exposed to BD at different concentrations, the THB-Val was formed in 3 – 
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32 times greater amount than the HB-Val adducts formed from EB by reaction at 
carbon position 1 (C1) (153, 156). The given ratio was higher at the lowest BD 
exposure concentrations. THB-Val has also been monitored in BD workers in 
China and Czech Republic (162, 163). The mean THB-Val concentration was 
significantly higher in BD exposed group (2 -21 ppm) than unexposed group (40).  
 Recently, a DEB-specific valine adduct, N, N-(2, 3-dihydroxy-1, 4-
butadiyl)-valine (pyr-Val), has been developed as a biomarker (165). Unlike THB-
Val and HB-Val, pyr-Val adduct is quantified as a peptide by immunoaffinity (IA)-
LC-ESI-MS/MS (86, 157). For these methods hemoglobin is digested with trypsin 
to release N-terminal peptides (1-7), which has been spiked with a synthetic 
deuterated pyr-Val peptide (1-11) as an internal standard. The pyr-Val peptides 
are purified and enriched from the trypsin digest with immunoaffinity column prior 
to LC-ESI-MS/MS analysis. Pyr-Val has been monitored in laboratory animals 
exposed to BD (151, 157).  A 10 to 60 fold greater concentration of pyr-Val was 
observed in mice as compared to rats ranging from low to high BD exposure ( 0.1 
– 625 ppm BD) (151). 
 In addition, the same approach was developed for analysis of the EB-
specific; HB-Val, adduct in rats exposed to 1,000 ppm BD for 90 days (158). The 
analysis of HB-Val by using (IA)-LC-ESI-MS/MS has advantages over N-alkyl 
Edman method. The new method demonstrated excellent reproducibility with a 
CV < 25% and sensitivity with LOQ 100 fmol/injection. However, this current 
method described above is not available for analysis of THB-Val. Consequently, 
the application of the method for pyr-Val and HB-Val are labor intensive requiring 
extensive sample processing time. 
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 Therefore, this research describes the development of sensitive and 
specific combined method based on IA coupled with LC-ESI- MS/MS which 
makes it possible to measure all three BD globin adducts in rodents samples 
exposed to BD. This information may be used to estimate rodent cancer 
incidence. 
 
1.4.2 DNA adducts 
 DNA adduct formation by the three major BD metabolites is complicated 
by the fact that the three electrophillic intermediates exist in more than one 
stereoisomeric form (85, 159–160). EB has one such asymmetric center that 
allows for two stereoisomeric forms, referred to as (S) and (R) isomers. DEB has 
two asymmetric centers that allow for three stereoisomeric forms: the (S,S), and 
(R,R) forms, and a third meso form (Figure 1.4), in which one center has the S 
and the other center has the R configuration to produce overall symmetry in the 
molecule. An isomeric mixture of DEB contains both the (S,S) and (R,R) forms. 
Hydration of these stereoismeric forms of DEB can result in four stereoisomers of 
EB-diol: the (2S,3R), (2R,3S), (2R,3R), and (2S,3S) forms. Therefore, the 
metabolism of BD can yield nine different stereoisomeric forms of three 
electrophillic intermediates which can potentially form DNA adducts (161).    
 
1.4.2.1 EB-produced DNA adducts 
 In vitro studies that have reacted various nucleobase/DNA targets with EB 
have repeatedly identified regioisomeric adducts at the N7 position of guanine 
(N7G) as the most abundant adducts (162–170). These adducts are 
hydrolytically unstable, with half-lives varying from 50 to 90 hours. EB also forms 
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two regioisomeric N3 adenine (N3A) adducts in vitro in calf thymus DNA that are 
lost by spontaneous depurination even more rapidly than the N7G adducts (167). 
Regioisomeric N1A and N6A adducts, being a Dimroth rearrangements of the N1 
adducts also occur(171). Tretyakova et al. (1997c) identified adenine adducts in 
EB-treated DNA formed at approximately 1/10 the abundance of the guanine 
adducts (169).  
Several N7-guanine DNA monoadducts of BD, N7-(2-hydroxy-3-buten-1-
yl) guanine (HB-GI) have been quantified in laboratory animals exposed to 14C-
BD and 14C-EB (163, 172).  Although somewhat greater numbers of adducts 
were observed in mice compared to rats exposed to the same concentrations of 
BD, these differences cannot explain the ~100 fold greater sensitivity of mice to 
BD-induced cancer.  Furthermore, because in these studies adduct 
concentrations were determined by measuring radioactivity of DNA and DNA 
hydrolysates, no structural information on the adduct was obtained. Later, 
Koivisto et al. (1995) employed 32P-postlabeling to quantify N7G and, N1A 
adducts in laboratory animals exposed to 1, 3-butadiene (171, 173–176).  N7G 
adduct levels were ~100 fold higher than the concentrations of N1A adducts.  In 
1999, Koc et al. measured N-7 guanine adduct formation, N-7-(2-hydroxy-3-
buten-1-yl)guanine (EB-Gua I), and N-7-(1-hydroxy-3-buten-2-yl)guanine (EB-
Gua II), using neutral thermal hydrolysis, desalted on solid-phase extraction 
cartridges, and quantitated by LC/ESI(+)/MS/MS (190).  The studied was 
performed in liver, lung, and kidney tissue of B6C3F1 mice and F344 rats 
exposed to 0, 20, 62.5, or 625 ppm BD. EB-Gua adducts had a linear exposure-
response relationship in both species. When the numbers of EB-Gua adducts in 
rats and mice were compared, the numbers in mice were about twice those in 
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liver and lung DNA at 625 ppm, while the difference in kidney at this exposure 
level was not significant.  
 
1.4.2.2 DEB-produced DNA adducts 
 DEB produces both monoadducts and bifunctional adducts. Reaction of 
the two epoxide sites of DEB with sites on two nearby nucleobases joins the two 
nucleobases, forming an inter- or intrastrand cross-links in double-stranded DNA. 
DEB treatment of deoxyguanosine has produced seven major and a variety of 
additional monofunctional adducts at the N7, N1, or an N position, with two being 
ring-structured compounds (177–179). Alkylation at the N7 position was the most 
rapid, producing abundant N7-trihydroxybutylguanine (N7THBG). DEB also 
produces an adenine monoadduct involving the N6 position after treating 
deoxyadenosine, calf thymus DNA, or Chinese hamster ovary (CHO) cells in 
culture (180 -181). Subsequent in vitro studies have verified that DEB produces 
monofunctional adenine adducts at this position, as well as at the N1, N3, N7, 
and N9 positions (170, 182–183). Extensive investigations have demonstrated 
that DEB produces bifunctional DNA adducts linking guanine with guanine and 
guanine with adenine, producing both inter- and intrastrand DNA cross-linking 
(184–186). Park and Tretyakova (2004) showed that low concentrations of DEB 
reacted with calf thymus DNA yielding equivalent amounts of the bis-N7G-BD 
bifunctional adducts and the corresponding N7THBG monoadducts, but that the 
former were more stable (81.5-h half-life) than the latter (48.5-h half-life).  
Stereochemistry is important in the formation of bis-N7G-BD inter- and 
interstrand DNA cross-links (187). (S,S)-DEB produced 8- and 10-fold more of 
the interstrand lesions than did the (R,R)- and meso-DEB, respectively. The 
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intrastrand cross-links formed by (R,R)- and meso-DEB accounted for 19% and 
51% of the total bis-N7G-BD adducts produced by these two isomeric forms of 
DEB, respectively.  Racemic DEB was reacted with calf thymus DNA to produce 
four asymmetrical guanine-adenine bifunctional adducts (188). Two were 
hydrolytically stable, indicating that these lesions have the potential to 
accumulate in DNA in vivo. 
Chronic BD inhalation studies in B6C3F1 mice demonstrated male and 
female mice had tumors of similar tissues, but for the most part females 
developed tumors at lower exposure concentrations.  For example, lung and liver 
tumors in female mice were observed at exposure concentrations of 6.25 and 20 
ppm BD, respectively.  By comparison with male mice, the respective exposure 
concentrations required a 10-fold increase in concentration.  There are also 
gender differences in the formation or repair of bis-N7G-BD adduct in male and 
female exposed to 625 and 200 ppm BD for two weeks.  Bis-N7G-BD adduct 
amounts in female mice are 2- to 2.5- fold higher than in male mice (189).  Some 
studies have explained this gender difference in neoplasia, MFs, and amount of 
adduct formed due to differences in BD metabolism, especially of DEB. 
 
 
1.4.2.3 EB diol-produced DNA adducts 
Zhao et al. (1998) were still able to detect N1-(2,3,4-trihydroxybut-1-
yl)adenine (N1-THB-A) adducts in human lymphocytes obtained from 14 
butadiene industry workers. N1-THB-A adducts (4.5 ± 7.7 adducts/109 
nucleotides) were observed in BD-exposed workers, while only 0.8 ± 1.2 
adducts/109 nucleotides were measured in non-BD exposed individuals (183). 
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The problem with using radiolabeled carcinogens and 32P-postlabeling analysis of 
DNA adducts is that these methodologies do not yield any structural information 
and they do not have internal standards to assure accurate quantitation.  
N7-(2’,3’,4’-trihydroxybut-1’-yl)guanine (THB-G) adducts of BD have been 
quantified in rodents exposed to BD using isotope dilution mass spectrometry 
(170, 190, 191). These adducts can result either from guanine reactions with 
DEB, followed by hydrolysis of the second epoxide, or directly by guanine 
alkylation by EB-diol.  EB-diol is much more abundant than DEB, and 98% of 
THB-G observed in vivo is produced from the reaction of EB-diol with DNA (190).  
Furthermore, only a 2 fold difference in THB-G levels was observed between 
mice and rats (190), which is inconsistent with the 100-fold difference in 
mutagenicity among the two species and suggests that DNA adducts other than 
THB-G monoadducts are responsible for the genotoxic effects of BD.   
 
1.4.3 DNA-Protein crosslink (DPC) 
 The adverse biological effects of DEB have been attributed to its ability to 
cross-link cellular biomolecules. Initial alkylation of adenine and guanine bases in 
DNA by DEB produces 2-hydroxy-3,4-epoxybut-1-yl (HEB) lesions, which contain 
an inherently reactive oxirane group that can alkylate neighboring nucleobases 
within the DNA duplex to form DNA−DNA cross-links (184). Alternatively, the 3,4-
epoxy ring can be subject to nucleophilic attack by amino acid side chains of 
neighboring proteins, giving rise to DPCs (Figure 1.5) (50, 192). Therefore, 
measuring DPC can indicate the dose of DEB at a critical target site. DPC by 
DEB was first observed by Jelitto et al. (1989) who employed alkaline elution 
methodology to detect DPC formation in liver and lung tissue of B6C3F1 mice 
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and SD rats following exposure to BD (193). This observation was subsequently 
confirmed by other groups that utilized biophysical methods for detecting DEB-
induced DPCs in mice, but not to the same extent in the rat (194).  Vangala et al. 
(1993) detected an increase in DPC activity in lung and liver, with increasing 
exposure concentrations of BD (100 ppm -2000 ppm). DPCs are more 
pronounced in mouse lung than in mouse liver. No such signs of genotoxicity 
could be observed for the lungs of rats (194).  
Michaelson-Richie et al. (2010) have observed DPCs in human cervical 
carcinoma cells (HeLa nuclear protein extracts) using an HPLC-ESI-MS/MS 
method (195). This observation positively identified DPC between cysteine thiols 
within proteins and the N-7 guanine positions within DNA. Similar studies have 
not been reported in rodent or human tissues, but it is likely that they will form 
proportionate to DEB formation. The ability of specific proteins to form DPCs is 
likely to be influenced by a number of factors, including protein abundance, 
structure, and cellular and nuclear localization. For example, DNA-binding 
proteins are in close proximity to DNA and readily available to form DPCs in the 
presence of cross-linking agents such as DEB. Several of the proteins found to 
form DEB-mediated DPCs, such as those involved in DNA replication and repair, 
are known to associate with DNA in the nucleus. For example, the DNA repair 
protein poly [ADP-ribose] polymerase I (PARP) is involved in the DNA damage 
signaling response, and has been previously shown to form cross-links to DNA 
as a result of exposure to nitrogen mustards (196), ionizing radiation (197), and 
formaldehyde (198). No DPC lesions involving histone proteins were detected, 
which could be a result of their low concentrations in nuclear protein extracts, 
their inefficient cross-linking to DNA, or their disrupted association with DNA 
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(199). Although the biological relevance of DEB-mediated DPC is poorly 
understood and very limited, certain types of DPCs persist through several cycles 
of DNA replication (200–201), potentially leading to cytotoxic and mutagenic 
outcomes such as sister chromatid exchanges and large deletions. The formation 
of these bulky, helix-distorting lesions would have the potential to interfere with 
the critical cellular process such as replication, transcription, and triggering 
programmed cell death or inducing genotoxicity. 
 
1.5 Multiplicative risk model for 1,3-butadiene cancer risk estimation 
1.5.1 Internal formation dose (D) 
 A dose concept for genotoxic electrophiles agents has been developed 
(202) where the dose is defined as the time-integrated concentrations of ultimate 
genotoxic agents. It is expressed in mmol × Kg-1× h (mMh) that are proportional 
to frequencies of potentially genotoxic events. 
 The key event in the carcinogenic action of genotoxic agents (reactive 
chemicals) is mutation (203, 204) induced via chemical changes in DNA. 
 The internal dose at target tissue of chemical is defined by:  
 
 
   
 
Where D is the integral over time (t) of the concentration, C(t) in target cells of a 
reactive chemical or metabolite (205). A chemical dose thus defined will be 
proportional to the frequency of potentially mutagenic DNA changes. At the 
present state of knowledge, the dose accordingly will be proportional to the area 
under the curve of the concentration and time curve (AUC). 
( Eq. 1) 
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 In this research, the internal dose of the reactive epoxide metabolites (EB, 
DEB, and EB-diol) will be calculated from levels of hemoglobin adducts in 
rodents exposed to BD in short-term experiments (10 days). Proportionalities 
between rates of formation of Hb adducts in different organs provide a good 
surrogate monitor for target doses (206). Internal formation dose in blood could 
be inferred from measurement of Hb adduct levels in short-term experiments with 
animals, if the rate constant for the reaction is known (in this case, the formation 
of an adduct to NH2-terminal valine in Hb; therefore, the simple expression for 
internal formation dose (D) when the adduct level is measured a short time after 
acute exposure. 
D =  A / Kval  
Where A is the Hb adduct level for the individual reactive epoxide in [ mol × g-1], 
Kval is the rate constant of adduct formation to NH2-terminal valine in [ L× g-1×h-
1] specific for the individual reactive epoxide in each species. 
 
1.5.2 1,3-Butadiene cancer risk estimation  
 Cancer risk estimation on the basis of internal dose of a genotoxic 
chemical is important for the detection and the assessment of cancer risk factors. 
An improving approach for risk estimation, the multiplicative risk model, is being 
developed, which is based on experience from ionizing radiation (207, 208). 
Evaluations of animal cancer tests using this approach indicate that a 
multiplicative cancer risk model could be applied to genotoxic chemical (202). 
According to that result, the cancer risk increment is proportional to the internal 
dose of causative genotoxic agent and its genotoxic potency specific for the 
studied species, strain and gender. In addition, it is indicated that the relative risk 
( Eq.2) 
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increment according to this model is common for different responding sites. 
Therefore, the model has been shown to provide a prediction of a tumor 
incidence in long-term animal cancer tests with genotoxic agents, and this model 
can be used for extrapolation of human cancer risk (208). Moreover, the 
applicability of the multiplicative risk model to cancer test data for ethylene oxide 
(207), acrylamide (209), and 1,3-butadiene (210) has been evaluated. It has 
been shown that internal dose of genotoxic agent and the observed tumor 
incidence in animal cancer test are well correlated with the predicted incidences 
from the multiplicative risk model. Furthermore, the model can be applied to 
genotoxic agents and the interspecies extrapolation can be performed. 
 In the assessment of cancer risk estimation from exposure to genotoxic 
agent, the multiplicative risk model is applied by:  
Pi(D) = 1 –  e-Piº (1+ßD)     (Eq.3) 
Where D denotes the internal dose in target tissue, and Pi0 represent the 
cumulative hazard for tumor formation in the target tissue, and i is tumor 
incidence among unexposed animals (the background risk), and ß is the common 
relative excess risk per unit of dose. The parameters of this nonlinear function will 
be estimated by a binomial regression model with 95% confidence intervals. The 
fit of model is presented as observed versus predicted tumor incidence. 
 
1.6 Research goal and specific aims 
In cancer epidemiology and cancer studies of BD, three epoxides are 
associated with the carcinogenic potency in rodents and humans. This is 
considered to be related to the metabolism of BD to its individual epoxide 
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metabolites and their different mutagenic potency. Therefore, it is important to 
measure the internal dose of individual epoxides in order to understand species 
and gender differences in metabolism and mutagenesis. N-terminal globin 
adducts of the three BD epoxides is an effective biomarker used to monitor the 
exposure and internal dose. One of the main aims of this research is to develop 
specific analytical methods that allow for quantification of all three BD epoxides in 
a single processing. Furthermore, the prediction of the response in cancer tests 
to the internal dose (globin adducts levels) and the relative mutagenic potency 
(from in vitro data) of the BD epoxide, will be evaluated with the application of a 
multiplicative cancer risk model.  
The goal of this research is to gain the information of the cancer risk 
estimation of animal cancer tests on the basis of internal dose, using globin 
adducts as a biomarker, to help us to better understand BD metabolism and 
carcinogenicity. This information will provide critical data to improve the cancer 
risk assessment for BD. The specific aims for this research are as follows: 
1. Develop a highly specific method for synthesis and characterization of 
butadiene epoxide alkylated peptide utilizing adducted peptides as analyte  
standards and internal standards for quantification of globin adduct in 
animal samples. 
2. Establish a sensitive method for peptide quantitation based on the 
analysis of their amino acid components using ultra performance UPLC-
MS/MS.  
3. Develop an improved method for simultaneous analysis of all three 
adducts formed by butadiene epoxides at the N-terminal valine of globin 
alpha chain in animals exposed to butadiene via inhalation. 
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4. Evaluate differences in cancer outcome of animals exposed to BD using 
an internal adduct dose of epoxides metabolites; EB, DEB, and EB-diol, 
and their relative genotoxic potency as the estimators. 
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FIGURES 
 
 
   
 
 
 
 
 
 
 
Figure 1.1 Molecular structure and relative molecular mass of BD 
 
 
 
 
 
 
 
 
 
 
 
 
 
Molecular mass: 54.09 
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Figure 1.2  Metabolism of BD. Showing enzymes involved in BD metabolism 
and the major detoxification metabolites excreted in urine 
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Figure 1.3 BD metabolism and formation of N-terminal valine adducts 
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Figure 1.4 Metabolic activation of BD to reactive electrophiles and the 
formation of DNA adduct 
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Figure 1.5 Metabolic activation of BD to reactive electrophiles and the 
formation of DNA-Protein crosslink (DPC) 
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Table 1: Survival-adjusted percentage for B6C3F1 mice and F344 rats in the long-term inhalation studies of BD [NTP 1993] 
 
Mice Exposure concentration (ppm) 
Sex Neoplastic lesion          Target organ  0 6.25 20 62.5 200      625 
Males       
                                                                                     
Initial number a 
 
Number of survivors 
 
- Malignant lymphomas                   All 
 
- Haemangiosarcoma                      Heart 
 
- Alveolar/bronchiolar carcinoma    Lung 
 
- Papilloma and carcinoma             Forestomach 
 
- Adenoma and adenocarcinoma   Harderian gland 
 
- Hepatocellular carcinoma             Liver 
 
Females       
                                                                                     
Initial number a 
 
Number of survivors 
 
-     Malignant lymphomas              All 
 
-     Haemangiosarcoma                Heart 
 
 
70 
 
35 
 
4 (9%)b 
 
0 (0%) 
 
22 (48%) 
 
1 (2%) 
 
6 (14%) 
 
31 (45%) 
 
 
 
70 
 
37 
 
10 (13%) 
 
0 (0%) 
 
 
70 
 
39 
 
3 (4%) 
 
0 (0%) 
 
23 (49%) 
 
0 (0%) 
 
7 (15%) 
 
27 (48%) 
 
 
 
70 
 
33 
 
14 (27%) 
 
0 (0%) 
 
 
70 
 
24 
 
8 (10%) 
 
1 (3%) 
 
20 (45%) 
 
0 (0%) 
 
11 (22%) 
 
35 (65%) 
 
 
 
70 
 
24 
 
18 (27%) 
 
0 (0%) 
 
 
70 
 
22 
 
11 (15%)c 
 
5 (14%)c 
 
33 (75%)c 
 
5 (3%) 
 
24 (51%)c 
 
32 (62%) 
 
 
 
70 
 
11 
 
10 (20%) 
 
1 (3%) 
 
 
70 
 
3 
 
9 (27%)c 
 
20 (64%)c 
 
42 (88%)c 
 
12 (29%)c 
 
33 (81%)c 
 
40 (86%) 
 
 
 
70 
 
0 
 
19 (40%)c 
 
20 (72%)c 
 
 
70 
 
0 
 
69 (97%)c 
 
6 (53%)c 
 
12 (45%)c 
 
13 (54%)c 
 
7 (64%)c 
 
12 (61%) 
 
 
 
70 
 
0 
 
43 (86%)c 
 
26 (83%)c 
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Mice Exposure concentration (ppm) 
Sex Neoplastic lesion          Target organ  0 6.25 20 62.5 200 625 
 
- Alveolar/bronchiolar carcinoma    Lung 
 
- Papilloma and carcinoma             Forestomach 
 
- Adenoma and adenocarcinoma   Harderian gland 
 
- Hepatocellular carcinoma             Liver 
 
- Adenocarcinoma                          Mammary gland 
 
- Benign and malignant                  Ovarian 
granulose cell 
 
4 (9%) 
 
0 (0%) 
 
9 (18%) 
 
17 (33%) 
 
0 (0%) 
 
1 (2%) 
 
15 (33%) 
 
0 (0%) 
 
10 (23%) 
 
20 (30%) 
 
2 (5%) 
 
0 (0%) 
 
19 (47%) 
 
3 (8%) 
 
7 (17%) 
 
23 (36%) 
 
2 (10%) 
 
2 (3%) 
 
27 (61%)c 
 
4 (6%) 
 
16 (41%) 
 
24 (51%)c 
 
6 (33%)c 
 
9 (26%)c 
 
32 (81%)c 
 
7 (23%)c 
 
22 (71%)c 
 
20 (65%)c 
 
13 (57%)c 
 
11 (41%)c 
 
25 (83%)c 
 
28 (83%)c 
 
7 (58%)c 
 
3 (22%) 
 
13 (67%)c 
 
6 (47%) 
 
Rats 
 
Exposure concentration (ppm) 
Sex Neoplastic lesion          Target organ  0 1,000 8,000 
Males       
                                                                                     
Initial number a 
 
Number of survivors 
 
- Exocrine adenoma                      Pancreas 
 
- Glial cell                                      Brain 
 
- Leydig cell tumor                        Testis 
 
 
110 
 
55 
 
3 (3%)b 
 
1 (1%) 
 
0 (0%) 
 
 
110 
 
50 
 
1(1%) 
 
4 (4%) 
 
3 (3%) 
 
 
110 
 
69 
 
10 (10%) 
 
5 (5%) 
 
8 (8%)c 
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Rats 
 
Exposure concentration (ppm) 
Sex Neoplastic lesion          Target organ  0 1,000 8,000 
 
Females 
 
Initial number a 
 
Number of survivors 
 
• Sarcoma                                  Uterus 
 
• Follicular cell adenoma           Thyroid gland 
 
• Benign or malignant                Mammary gland 
 
• Carcinoma                              Zymbal gland 
 
 
 
 
110 
 
60 
 
1 (1%) 
 
0 (0%) 
 
50 (50%) 
 
0 (0%) 
 
 
 
110 
 
68 
 
4 (4%) 
 
2 (2%) 
 
79 (79%) 
 
0 (0%) 
 
 
 
110 
 
76 
 
5 (5%) 
 
10 (10%)c 
 
81 (81%)c 
 
4 (4%) 
 
From  Melnick et al (1990); National Toxicology Program (1993); Owen (1987); Owen (1993) 
aInitial numbers include animals removed from study for interim sacrifies. 
bMortality-adjusted tumor rates are given in parentheses. 
cp < 0.05, based on regression analysis with adjustment for intercurrent mortality. 
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CHAPTER II 
 
SYNTHESIS AND CHARACTERIZATION OF STANDARD PEPTIDES 
SPECIFIC FOR 1,3-BUTADIENE N-TERMINAL VALINE ADDUCTS 
 
 
2.1 Abstract 
Butadiene (BD) is an industrial chemical used in the production of 
synthetic rubber and found in gasoline and combustion products. It is a multi-site 
and multi-species carcinogen in rodents with mice being much more sensitive 
than rats. BD is metabolized mainly by P450 2E1 to 1,2-epoxy-3-butene (EB), 
1,2;3,4-diepoxybutane (DEB) and 1,2-epoxy-3,4-butanediol (EB-diol). For risk 
assessment, the internal formation of each epoxide can inform their relative risks 
because they show significantly different mutagenicity. The measurement of N-
terminal valine adduct in globin chains can be used as a biomarker to determine 
the internal formation dose of each epoxide after exposure to BD. In this chapter, 
we needed to prepare pure and rigorously characterized epoxide alkylated N-
terminal glycopeptides of rat and mouse for using in an immunoaffinity purification 
step and to standardize the assay. In addition, we needed a pure isotope-labeled 
peptide to serve as an internal standard for quantitation by LC-MS. We therefore 
synthesized the alkylated peptides using in vitro direct alkylation of the peptide 
reaction with EB and EB-diol.  
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The peptides were purified by HPLC and characterized by their 
fragmentation patterns obtained by tandem mass spectrometry (MS/MS). Use of 
isotope labeled [13C15N5] on N-terminal valine in the oligopeptide synthesis 
provided the required isotopic labeled peptide for use as an internal standard. 
This strategy enabled us to obtain pure and well characterized alkylated analyte 
standard peptides for quantification of globin adducts in rodent samples exposed 
to BD.  
 
2.2 Introduction 
 1,3-Butadiene (BD) is an important industrial chemical wildly used for 
synthetic rubber and resin production (1). It has been identified as an 
environmental contaminate in gasoline, motor vehicle exhaust, and cigarette 
smoke (2, 3). BD was recently reclassified as a human carcinogen following 
inhalation exposure by the US EPA (4) and IARC (5). This classification was 
based on epidemiologic studies of exposed workers in the butadiene rubber 
industry and laboratory animal data. Human epidemiologic studies of 
occupationally exposed workers have presented evidence for an increased 
incidence of leukemia, lymphatic and hematopoietic cancer (6–8). In chronic 
inhalation experiments with B6C3F1 mice and Sprague-Dawley rats, BD was 
carcinogenic in both species (9, 10). However, while mice developed tumors after 
chronic exposure to as little as 6.25 ppm BD (9), much higher concentrations 
(1,000 ppm) were reported to induce tumors in rats (10). These interspecies 
differences in sensitivity have been attributed to differences in BD metabolism in 
mice and rats, in particular, the increased formation of reactive epoxides 
metabolites in the mouse (9). 
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BD requires metabolic activation by the cytochrome P450 forming reactive 
epoxides: 1,2-epoxybutene (EB), 1,2:3,4-diepoxybutane (DEB) and 3,4-epoxy-
1,2-butanediol (EB-diol) (1) that are known to covalently bind to DNA and 
hemoglobin. Hemoglobin adducts, especially adducts at the N-terminus, have 
been successfully used as biomarkers of exposure to reactive chemicals such as 
acrylamide, ethylene oxide, and butadiene (11–14). The BD derived N-terminal 
globin adducts 2-hydroxy-3-butenyl-valine (HB-Val), N,N-(2,3-dihydroxy-1,4-
butadyil)-valine (pyr-Val), and 2,3,4-trihydroxybutyl-valine (THB-Val) are used as 
biomarkers for EB, DEB, and EB-diol, respectively. A simplified pathway for 
metabolism and globin adduct formation of BD is shown in Figure 2.1. 
 Currently, a sensitive immunoaffinity (IA)-LC-MS/MS technique for 
quantitation of the cyclic adduct, pyr-Val, has been refined to the point of practical 
application to the routine analysis (15). In addition, Georgeiva et al. (2010) 
provided the basis for a more sensitive ultra performance liquid chromatographic 
– mass spectrometry (UPLC-MS/MS) assay for quantitative measurement in 
globin of rodents exposed to BD (16). Both HB-Val and THB-Val adducts in 
rodents and humans have been quantitated using the “modified Edman 
degradation method” (17, 18), with modifications in the extraction of formed 
pentafluorophynylthiohydantoin (PFPTH) (19) and analysis by GC-MS/MS. This 
method had lacked sensitivity for HB-Val analysis and had a poor recovery of 
analyte and internal standard for THB-Val analysis. Therefore, the objective of 
this research was to develop a specific and sensitive assay for detecting all three 
reactive epoxides adducts using IA-LC-MS/MS. 
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 IA-LC-MS/MS has been developed based on enzymatic hydrolysis of 
globin for measurement of adducts to N-terminal valine formed from BD reactive 
epoxides (13). The most commonly used protease enzyme is trypsin, which 
hydrolyses the peptide bonds at the carbonyl groups of lysine (K) and arginine 
(R). The N-terminal peptides of the alpha-chain formed after tryptic hydrolysis of 
globin are heptapeptides, specific to mouse and rat (Table 2.1).  
 Key to adapting the trypsin digestion procedure for application to rodent 
samples is the availability of a pure and well characterized, isotope-modified N-
terminal sequence of rodent globin alpha chain to serve as an internal standard 
peptide. There are several approaches available to synthesize the analyte 
standard and internal standard peptide. However, these approaches are not 
suitable for synthesis of all three epoxides standard peptides due to the different 
structure and position of the carboxylic group on an alkylated peptide chain. 
Recently, the corresponding alkylated pyr-Val (1-11) and pyr-Val [2H3] (1-11) 
peptides were synthesized by our group and used as analyte and internal 
standards, respectively (20). Valine at the N-terminal was alkylated with DEB to 
give pyr-Val after protection of the carboxylic group with di-O-tert-butyl derivatives 
(t-boc). However, the method was not efficient enough to synthesize the HB-Val 
and THB-Val standards. In the present work, the analyte and internal standard 
peptides were synthesized using direct alkylation reaction between (1-11) globin 
peptides and 1,2-epoxybutene (EB) or 3,4-epoxy-1,2-butanediol (EB-diol). 
  
2.3 Materials and methods 
 Materials. (±)-1,3-butadiene monoxide (EB, 98%) was obtained from 
Sigma-Aldrich Chemical Co. (St. Louis, MO). 1,3-butadiene diolepoxide (EB-diol) 
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was generously provided by Dr. Avram Gold and Dr. Louise M. Ball from 
Department of Environmental Science and Engineering, The University of North 
Carolina at Chapel Hill. The N-terminal valine alpha chain peptides of mouse and 
rat globin (1-11) (Table 2.1) were synthesized by the peptide synthesis facility 
core at the University of North Carolina at Chapel Hill. The corresponding 
[13C15N5] 1-11 peptides of mouse and rat were also obtained from the peptide 
synthesis facility core. The purity of the peptides was greater than 98% on the 
basis of high performance liquid chromatography (HPLC) analysis. Trypsin 
(biotin-agarose) from bovine pancreas and all other chemicals, mass 
spectrometry grade, were purchased from Sigma-Aldrich Chemical.  
 A Surveyor HPLC system (ThermoFinnigan, San Jose, CA) connected to 
an LCQ Deca ion trap mass spectrometer (ThermoFinnigan) was used in all 
analyses.  
 Methods 
Alkylation and purification of standard peptides 
 Direct alkylation method 
 N-terminal alpha chain (1-11) peptides and the stable isotope [13C15N5] 
labeled peptides were incubated with EB or EB-diol at 1:20, 1:50, 1:100, or 1:200 
peptide to epoxide molar ratios for 3 days at 37ºC. Total volume was adjusted to 
1.5 mL with 0.1 M ammonium bicarbonate buffer with different pH levels; 6.5, 7.5, 
and 8.5,  to determine the optimum peptide ratio and pH for EB and EB-diol 
peptide alkylation. After incubation, the reactions were stopped with 20% formic 
acid and the pH was adjusted to strong acid conditions (pH 2). 
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Purification of standard peptides  
 Alkylated peptides were purified by HPLC equipped with a quaternary 
pump coupled with LCQ-Deca electrospray ionization (ESI)/ion trap mass- 
spectrometer. The fraction collection was automatically performed by LCQ-Deca 
system. Separation was obtained at room temperature with a Vydac C18 (150 × 
2.1 mm) HPLC column (Grace, Deerfield, IL). The LC solvents were 15 mM 
ammonium formate (A) and methanol (B). Separation was achieved at 400 
µL/min with a gradient of 5% - 50% B over 20 minutes. After separation, the 
column was washed at 80% B for 5 minutes and equilibrated at 5% B for 5 min. 
The monoalkylated peptide fraction was collected every 30 min (0.4 mL per 
fraction). All fractions were pooled and assessed for the presence and purity of 
the monoalkylated peptide of interest by HPLC-MS as described below. Fractions 
containing alkylated peptides were stored at -20 ºC until use. 
 
Assessment of purified monoalkylated peptides 
 The LC-MS was performed in a LCQ-Deca mass spectrometer equipped 
with a ESI ion source interface. Column and chromatographic conditions were the 
same as those in the previously described in purification step. The mass 
spectrometer was set up to obtain full scan MS spectra (Scan range: 200 – 2000) 
with a positive ion injection mode. 
 
Characterization of standard peptides 
 Following the HPLC-MS purification and assessment, purified 
monoalkylated peptides were characterized by full scan MS/MS to confirm ion 
fragments (y-fragments and b-fragments). Full scan MS/MS spectra in the linear 
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ion trap were obtained by collision-induced dissociation (CID) at a normalized 
collision energy of 35% as the activation mode. The activation time of 30 ms was 
used for selecting the precursor ion. 
 
2.4 Results and discussion 
 The aim of this study was to synthesize, purify, and rigorously characterize 
standard peptides in quantities for tuning analytical equipment and quantification 
of BD derived globin adducts. Standard peptides were successfully synthesized 
using the direct alkylation method.  
 
Optimization of the reactions in direct alkylation method 
 The purpose of this experiment was to optimize the conditions for direct 
alkylation of peptides with BD monoepoxide (EB, EB-diol) over concentrations 
(molar ratios) and pH. Concentration of the peptides and pH were adjusted in 
order to increase the reactivity of valine (V) at the N-terminal site and to minimize 
the alkylation of lysine (K) and also cross-linking between peptides (21). The 
highest yields of monoalkylated peptides was found at 1:100 and 1:20 molar 
ratios for EB and EB-diol standard peptides, respectively. These reactions were 
performed at 37 ºC for 3 days, which was adjusted from Fred et al. (2004) (13). 
This experiment showed that the reaction of EB with peptides was less efficient in 
alkylation than the reaction of EB-diol. In order to obtain high yields for the EB 
alkylated product, higher amounts of EB was needed for the reaction. 
 In our experiment, the alkylated peptide reactions with EB and EB-diol was 
achieved at pH 6.5 (Figure 2.2). At this pH, the reaction mixture revealed three 
products, the major being monoalkylated peptide and the two minor products 
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were unalkylated and dialkylated peptides. It was important to adjust pH in 0.1 M 
ammonium bicarbonate buffer at about 6.5 - 7 to decrease the reactivity of 
epoxide with lysine (K) (pKa = 8.95) at both positions 7 and 11 in the peptide 
sequence. 
 
Formation and purification of standard peptides  
 The alkylated peptides were synthesized by direct reacted the EB or EB-
diol with 1-11 globin peptide and the yield of alkylation was analyzed by HPLC-
MS. The (1-11) rat peptide (VLSADDKTNIK) and mouse peptide 
(VLSGEDKSNIK) incubated with EB, forming HB-Val analyte standard peptides, 
provided signals for singly-charged ion, (M + H)+, at m/z 1273.5 and 1259.5, 
respectively. These alkylation peptides were 70 Da higher than those of 
unalkylation peptides. Similarly, the (1-11) rat peptide and mouse peptide 
incubated with EB-diol gave signals for THB-Val analyte standard peptides singly 
charge ion, (M + H)+,  at m/z 1306.5 and m/z 1293.5, respectively, that were 104 
Da higher than unalkylation peptide. An increase of 70 Da and 104 Da for both 
peptides agreed with the incorporation of one EB or EB-diol equivalent, 
respectively. 
 Alkylated stable isotope [13C15N5] peptides was then used as an internal 
standard for correction the possible variation in yields during globin sample 
digestion. EB-alkylated and EB-diol -alkylated [13C15N5] peptides were reacted 
using the same approach as analyte standard peptides. They were 6 Da higher 
than analyte standards due to the mass unit of [13C15N5]. The representative ESI+-
MS ion spectrum of EB-alkylated internal standard peptide in rat is shown in 
Figure 2.3. 
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 More than 70% of the peptide was converted into the monoalkylation 
product and about 25% was converted to dialkylation. Under the conditions of this 
experiment, the alkylation reaction always yielded  monoalkylated and dialkylated 
peptides, which were well separated by HPLC at about 13 min from the total run 
time 30 min. The representative ESI+-MS ion spectrum of purified EB-alkylated 
internal standard peptide for rat is shown in Figure 2.4. The ion spectrum 
demonstrated purified monoalkylated rat internal standard peptide at m/z 
1279.74. This purification protocol provided a high yield of pure monoalkylated 
standard peptide.  
 
Characterization of standard peptides  
 All alkylated peptides were characterized by LCQ-DECA MS/MS. collision-
induced dissociation (CID) of the singly-charged ions of EB-alkylated peptide and 
EB-diol-alkylated peptide using ESI+-MS/MS in the positive ion mode, providing 
further information on the location of the epoxide-derived group within the 
peptides. For both epoxides, the CID spectra predominantly yielded modified b-
type fragment ions (b*) and y-type fragment ions (y*). Abundant modified ion 
fragments can be used to identify the alkylation position on peptides. 
Furthermore, CID of alkylated peptide also provides confirmation of amino acid 
position on the peptide chain, as several alkylated ions are observed. The 
representative ion fragments of EB alkylated peptide (HB-Val) and EB-diol 
alkylated peptide (THB-Val) in rat are shown in Figure 2.5a and Figure 2.5b, 
respectively. The scan range of MS/MS spectra was 350 -1500. For HB-Val 
standard peptide in rat (Figure 2.5a), the fragment ions at m/z 677, 805, and 906 
correspond to mass of aspartic acid (D), lysine (K), and threonine (T) on alkylated 
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peptide, respectively. The fragment ion at m/z 603 corresponds to only valine 
alkylation (*V). The lack of lysine alkylation (K*) in the peptide chain at m/z 671 
indicates that EB alkylation is located at N-terminal valine.  
  For the THB-Val standard peptide in rat (Figure 2.5b), consistent 
fragment ion chromatograms were obtained. The alkylation at N-terminal valine 
yielded an abundant of y5 ion at m/z 637. The b6 and b7 ions at m/z 711 and m/z 
839 corresponded to the alkylated fragments THB-VLSADD and THB-VLSADDK, 
respectively. These findings indicated that EB-diol alkylation was located at N-
terminal valine of peptide chain. 
 MS/MS chromatograms did not show any fragment ions correspond to the 
alkylation on both valine and lysine position at pH 6.5. This condition is well below 
the pKa of lysine at 8.95 – 10.53. Therefore, the amino group is mainly 
protonated, which may explain the inhibition of alkylation on this amino acid. 
These findings agree with previous reports from Fred et al. (13). 
 
2.5 Conclusion 
 The availability of suitable analyte and internal standard peptides is 
critical for the development of our analytical approach to quantify hemoglobin 
adduct biomarkers in biological samples. In this study, we report a direct 
alkylation method for the synthesis of (1-11) peptide standards for rat and mouse. 
This method successfully provided proper syntheses, purification, and 
characterization of both the analyte and internal standards. Our future goal is to 
use these standard peptides in the immunoaffinity purification step for 
quantification of globin adducts in rodent samples exposed to BD. 
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FIGURES 
 
 
 
 
Figure 2.1 BD metabolism and formation of N-terminal valine adducts 
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Figure 2.2 Effect of pH on peptide alkylation. LC/ESI+-MS ion spectrum of EB- 
internal standard peptide show the spectrums corresponding to the unalkylated, 
monoalkylated [M+H]+, and dialkylated [2M+H]+ peptide at 1202.74, 1279.74, and 
1349.74, respectively 
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Figure 2.3 Representative LC/ESI+-MS ion spectrum of EB-alkylated internal 
standard peptide in rat. The reaction was performed at molar ratio 1:100, pH 6.5 
at 37ºC for 3 days 
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Figure 2.4 Representative LC/ESI+-MS ion spectrum of purified EB-alkylated 
internal standard peptide in rat 
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Figure 2.5 MS/MS spectra of EB-alkylated peptide (a) and EB-diol-alkylated 
peptide (b) 
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TABLE 
 
Table 2.1 Butadiene epoxide containing at N-terminal peptides (1-11). 
 
 
Mouse:  EB or EB-diol-*Val-Leu-Ser-Gly-Glu-Asp-Lys/-Ser-Asn-Ile-Lys 
V  - L  -   S  - G  -  E  - D  -  K  - S  - N  - I  - K 
 
Rat:        EB or EB-diol-*Val-Leu-Ser-Ala-Asp-Asp-Lys/-Thr-Asn-Ile-Lys 
V  - L  -   S  -  A  - D  - D  -  K  -T  - N  - I  - K 
 
*  [13C15N5] in Internal standards 
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 CHAPTER III 
 
ACCURATE QUANTITATION OF STANDARD PEPTIDES USED FOR 
QUANTITATIVE PROTEOMICS 
 
This paper has been published and therefore is reproduced with permission 
from [ Narisa K. Bordeerat, Nadia I. Georgieva, David G. Klapper, Leonard B. 
Collins, Tyra J. Cross, Christoph H. Borchers, James A. Swenberg, and Gunnar 
Boysen. Accurate quantitation of standard peptides used for quantitative 
proteomics. Proteomics, 2009, August; 9(15): 3939–3944.] Copyright [2009] 
Wiley-vch Verlag GmbH & Co. KGaA, Weinheim. 
 
3.1 Abstract 
 Mass spectrometry-based proteomics has become an indispensable tool in 
system biology generating a need for accurate and precise quantitation of peptide 
standards. The presented method utilizes ultra performance liquid 
chromatography-tandem mass spectrometry (UPLC-MS/MS) to accurately 
quantify peptide standards at concentrations of 0.1-10 µM. The ability for accurate 
quantitation of micro-molar concentrations has the advantages that quantitation 
can be performed routinely with high precision and the high sensitivity of the 
method minimizes the amounts required. 
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3.2 Introduction 
 Mass spectrometry-based proteomics has evolved into an indispensable 
tool for molecular and cellular biology that will significantly contribute to the 
emerging field of systems biology. Early work focused on qualitative identification 
of proteins and peptides. More recently, there has been increasing interest in 
quantitative proteomics (1). Progress in the area of mass-spectrometry-based 
proteomics has been made using stable isotopes. Stable isotopes can be 
introduced chemically by reacting peptide digests with an isotope tag (ICAT) (2), 
or the iTRAQ method (3) which currently allows the quantitative comparison of up 
to 8 samples in a single analysis. Whole proteomes can be labeled metabolically 
during cell culture (SILAC) by providing stable isotope precursors using either 
stable-isotope-labeled amino acids (1, 4–7) or stable-isotope-labeled salts (8). 
Although these isotopic labeling techniques are very powerful for biomarker 
discovery studies, their expense precludes their use in studies involving large 
numbers of samples, such as biomarker verification or validation. Moreover, 
SILAC can only be used in cell culture, and not for clinical studies. 
Recently, there has been interest in label-free techniques, including GE 
Healthcare's DeCyder MS where two chromatograms are compared, the Empai 
scoring technique (9), ion accounting (10) and spectral counting (11, 12), where 
the relative abundances of peptides are used to give the relative abundances of 
proteins. Without stable-isotope-labeled standards, however, the effect of other 
components in the samples can cause suppression effects, as has been noted in 
our FIA-based metabolomics studies using high resolution FTICR (13), and even 
in other studies utilizing LC-MS/MS separation (14). This will probably mean that 
label-free methods will be limited to comparison of samples where the majority of 
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the components do not change – i.e., a set of samples where only the 
concentrations of a few components change, and the matrix is effectively the 
same for all of the samples in the set. 
A successful absolute quantitation of proteins can be achieved using 
double exact matching isotope dilution mass spectrometry (IDMS) as shown in 
the excellent paper of Burkitt et.al (15). Alternatively, this can be applied using 
custom-synthesized stable-isotope labeled standard peptides (16–19). These 
labeled standards can include peptides which contain post-translational 
modifications (for example, phosphorylation and chemical alkylation) (20). We 
have studied globin alkylation by chemical carcinogens for several years, and 
have established assays for specific quantitation of alkylated peptides which can 
be used as biomarkers for exposure assessment (21, 22). These assays are 
based on proteolysis with trypsin, immunoaffinity enrichment, and LC-MS/MS. 
Recently, we used a similar approach to develop an immunoaffinity MALDI-
MS/MS (iMALDI) assay for targeted protein quantitation (23). 
During these studies, however, it became obvious that accurate 
quantitation of the standard peptides was challenging. The reason for this is that 
the amounts of standard peptides available are usually so small that accurate 
weights cannot be obtained. Peptides are hygroscopic and easily absorb moisture 
from the air, and the presence of water and salts leads to overestimation of 
peptide amounts. We and other researchers have been forced to use a 
combination of weight, HPLC-UV, and LC-MS/MS for quantitation of peptide 
standards (24). However, this method is labor-intensive and is therefore not 
suitable for routine quantitation of peptides for multiplex proteomic applications, 
which may require thousands of standard peptides. 
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To overcome these limitations, we have developed a new approach for the 
peptide quantitation based on the analysis of their component amino acids after 
acid hydrolysis, using ultra performance liquid chromatography-tandem mass 
spectrometry (UPLC-MS/MS). The high specificity of MS/MS combined with fast 
chromatography makes this a suitable approach for high-throughput analyses. 
 
3.3 Materials and Methods 
Single standard amino acids were purchased from Sigma-Aldrich (St. 
Louis, MO), concentrated hydrochloric acid (12 N) from Fisher Scientific 
(Pittsburgh, PA), and all other reagents and solvents were ACS grade or higher. 
Amino acid standards for instrument calibration and the internal standard amino 
acid, norleucine, were prepared from single amino acid standards which are 
stable in 100 mM HCl solution. Stock solutions at 10 mM were made in water with 
0.1 mM HCl. Norleucine was added to each calibration standard and samples at a 
final concentration of 2.5 mM. 
The peptides were synthesized at a 5 µmol scale using Fmoc chemistry on 
a Prelude peptide synthesizer (Protein Technology, Tucson, AZ). The C-terminal 
amino acids were conjugated to TentaGel R resin (Rapp Polymere, Tübingen, 
Germany) and subsequent residues, at a concentration of 100 mM, were double 
coupled using 20% piperidine as the deprotector and 1H-benzotriazolium 1-
[bis(dimethylamino)methylene]-5chloro-,hexafluorophosphate (1),3-oxide (HCTU) 
as the activator. Cleavage and deprotection was performed with 95:2.5:2.5 
TFA:water:triisopropylsilane. The peptides were resolubilized in 0.1% TFA and 
purified by reverse-phase HPLC Ultimate 3000 (Dionex, Sunnyvale, CA) 
monitoring peptide elution at 230 nm using a Vydac C18 column (10 × 250 mm, 10 
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µm resin) with a linear gradient of 0.1% TFA in water (v/v) and 0.85% TFA in 50% 
acetonitrile (v/v) at a flow rate of 4 mL/minute over 60 min. The fractions of 
interest were spotted onto stainless steel MALDI plates and measured by MALDI-
TOF (Applied Biosystems/MDS SCIEX, Foster City, CA) mass spectrometry. 
Fractions containing greater than 80% of the target peptide were pooled and 
lyophilized. 
For HCl hydrolysis, peptide solutions were mixed with 10 µL of 20 µM 
norleucine, as internal standard, in a small culture vial and lyophilized in a 
vacuum centrifuge. The vials were placed inside a 10 mL glass container, 500 µL 
of 6N HCl were added to the bottom of the container, and the container was 
closed with an air tight PTFE lined cap. The vials were placed in an oven at 
150°C for 4 h, then cooled to room temperature for 30 min in a water bath to 
condense the acid vapor on the inside of the sample vials. Prior to analysis the 
hydrolysates were dried in a vacuum centrifuge for 15 min to remove traces of 
acid. 
The quantitative analysis of hydrolyzed peptide was performed with an 
UPLC (Waters, Milford, MA) coupled to a TSQ-Quantum ultra triple quadrupole 
mass analyzer (ThermoFinnigan, San Jose, CA). A 2.1 mm × 150 mm UPLC™ 
BEH SHIELD RP18 1.7 µm column was operated with a linear gradient from 20% 
methanol-0.1% formic acid to 80% methanol-0.1% formic acid for 7 min at a flow 
rate of 200 µL/min. The individual amino acids were monitored in selected 
reaction monitoring mode (SRM) (Figure 3.1 and Supplemental Table S1). 
Amounts of amino acids were calculated from the area ratio of the corresponding 
ion transitions of amino acids to ion transition of the internal standard, norleucine. 
Calibration curves of the area of amino acid over area of norleucine were 
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constructed daily, to guarantee linearity. Area ratios of analyte over internal 
standard were multiplied by the amount internal standard added and adjusted by 
a corresponding response factor to correct to difference in MS response. 
Calibration solution repeatedly showed linear response from 0.1 pmol up to 200 
pmol/injection (high amount injected) representing 4 orders of magnitude. 
 
3.4 Results and discussion 
 We have shown that all 20 common amino acids can be detected by 
UPLC-MS/MS analysis without any derivatization step (Figure 3.1). It is also 
shown that while accurate quantitation of all amino acids is desirable, using 1 to 
3, 5 or 6 amino acids for quantitation produced CVs of <17% and, the mean did 
not significantly change by increasing the number of amino acids used for 
quantitation. Thus we concluded that three amino acids were sufficient for 
accurate quantitation of peptide solutions. 
Method validation was assessed by analyzing the NIST standard peptide 
reference material 8327 three times on the same day and on three different days 
to obtain intraday and interday results (Supplemental Table S2). Therefore, 
hydrolyzed peptide solutions were initially quantified by the amounts of alanine, 
serine, proline, threonine, valine, leucine or isoleucine, if present. The mean 
relative standard deviations (RSD) for intraday and interday assay reproducibility 
(n=3) were 8% and 5%, respectively. Accuracies of the validation samples ranged 
from 95% to 110%. 
To illustrate that the complete hydrolysis of the standard peptide had been 
acheived, the release of the free amino acids from the peptide was monitored 
over time. The ratio of amino acid that was released from the peptide to the 
90 
 
internal standard amino acid (norleucine) that was added prior to hydrolysis was 
measured at several time points (1 h, 2 h, 4 h, 8 h, 16 h, and 24 h) after the start 
of the acid hydrolysis. Duplicate samples were analyzed for each time point and 
the release of six amino acids was monitored. Results for alanine, serine, proline, 
valine, threonine, and leucine are shown in supplement Figure S1. The result of 
this time course experiment indicated that hydrolysis need to be performed at 4 h 
since this time gave high yield of the six amino acids studied. Longer hydrolysis 
time (8-24 h) showed no difference in the yield. 
UPLC-MS/MS was chosen for the analysis of peptide hydrolysates 
because of its high speed and resolution and the advantage of automation of 
sample preparation and processing. Initially, multiple stable isotope labeled amino 
acids were used as internal standards, but the addition of 20 extra ion transitions 
significantly reduces the number of points over the peaks. Comparison of results 
between multiple stable isotope label amino acid and single amino acid 
(Norleucine) as the internal standard was performed. The result of peptide 
quantitation using 4 amino acids, their isotope-labeled counterparts and 
norleucine are shown in supplement Figures S2 & S3 and Table S3. No 
difference was found in the value measured for the concentration of peptide. 
Therefore, we decided to use a single internal standard for all amino acids and to 
correct for different MS response using a response factor obtained from 
calibration solution made from single amino acid standards since this has been 
shown to be sufficient using the NIST standard peptide reference material (Table 
S3). 
The study was extended to the analysis of standard peptides used for 
quantitative proteomic applications (Figure 3.2, and Supplemental Table S4). 
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These peptides were synthesized for projects that required absolute quantitation 
of proteins in biological samples. Usually, the peptides are quantified by micro-
weight and a minimum amount of 100 µg is required for these measurements. 
Quantitation by UPLC-MS/MS produces similar results to those previously 
determined by weight, but required less than 10 ng for accurate analysis. This 
represents a 10,000-fold increase in sensitivity without sacrifice of accuracy and 
specificity. Furthermore, ~30% of the peptide concentrations were not accurate 
based on weight quantitation. Thus, there is an unacceptable and unavoidable 
uncertainty using weight for standardization. 
The present method is about 5-fold more sensitive than a previously 
reported LC-MS/MS method for underivatized amino acids (13). Alternatively, 
Amino acid analysis can be performed accurately at the femtomole level by a 
method employing fluorescence detection after derivatization with o-
phthalaldehyde (OPA). However, inter-laboratories comparisons have shown high 
variability in the results due to inconsistency in derivatization conditions (14). 
These discrepancies between the methods and laboratories are probably caused 
by impurities (such as TFA salts) of the peptides and absorption of moisture 
during peptide handling. Precautions can be implemented to better assure purity 
of the standard peptides; however, as the number of peptide standards increases, 
it will be difficult to maintain high purity and accuracy due to the chemical nature 
of peptides. Therefore, the ability of accurate quantitation of peptide solutions at 
micromolar concentrations, instead of dry material has the advantage of avoiding 
inaccuracy due to weighing, chemical derivatization and errors during preparation 
of dilutions. In addition, the increased sensitivity reduces the amounts needed for 
analysis and reduces costs, especially if chemically unique peptides are needed. 
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One of the problems with the MS/MS methodology is the fact that isobaric 
amino acids, such as leucine, isoleucine, and norleucine often fragment very 
similarly. This limitation was overcome by utilization of UPLC which achieves 
baseline separation for these amino acids (Figure 3.3). In addition asparagine 
and aspartic acid were separated to avoid cross peaks form natural 13C isotopes 
(Figure 3.1). Unfortunately, the reported fast separation did not separate 
glutamine and glutamic acid and, therefore, glutamic acid cannot be used for 
quantitation if the peptides also contain glutamine. Further, the method was 
optimized for speed and analysis of known peptides. Therefore, the current 
approach is unsuitable for analysis of amino acid content in unknown proteins or 
biological specimens. For such traditional amino acid analyses a modified UPLC 
gradient can be applied to separate all amino acids by time (Data not shown). 
 Peptide concentrations of 0.1-10 µM could be analyzed with this method 
using as little as 10 µl of sample. This new method is more sensitive than other 
LC-MS/MS (13) and common methods like ion chromatography (IC) using 
ninhydrin post column derivatization (25), and gas chromatography/mass 
spectrometry (GC/MS) (26). Moreover, the specificity of single reaction monitoring 
mode allowed specific analysis of twenty amino acids in less than 10 min per 
sample, making it suitable for high through put analysis. 
 
3.5 Conclusion 
In conclusion, amino acid quantitation of peptide solutions by UPLC-
MS/MS is a viable alternative to traditional amino acid analysis methods or 
quantitation by weight. The UPLC-MS/MS method utilizes a few simple steps that 
can be completed within 6 h, which represents a great advantage over previous 
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GC/MS and IC/ninhydrin methods requiring derivatization and numerous steps for 
sample preparation. The ability to accurately quantitate µM solutions of peptides 
significantly reduces the amounts needed and allows for high throughput 
quantitative analysis of peptide standards. This method is expected to become a 
standard repertoire in proteomic laboratories. 
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FIGURES 
 
 
 
Figure 3.1 Extracted ion chromatograms for common amino acid standards 
and norleucine used as internal standard. * Indicates 13C-isotopes of isoleucine, 
leucine and norleucine 
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Figure 3.2 Representative extracted ion chromatograms of peptide hydrolysate 
determined by UPLC-MS/MS 
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Figure 3.3 Separation of isobaric amino acids leucine, isoleucine, and 
norleucine by UPLC-MS/MS 
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SUPPLEMENTAL TABLES AND FIGURES 
 
Table S1: List of ion transitions monitored for amino acid quantitation  
 
 
Amino Acid 
 
CID energy  
[eV] 
 
MS/MS 
transitions 
 
 
Retention time 
[min] 
 
Glycine 
Alanine 
Serine 
Proline 
Valine 
Threonine 
Cysteine 
Isoleucine 
Leucine 
Norleucine 
Asparagine 
Aspartic acid 
Glutamine 
Lysine 
Glutamic acid 
Methionine 
Histidine 
Phenylalanine 
Arginine 
Tyrosine 
Tryptophan 
 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
15 
15 
10 
10 
10 
10 
20 
10 
10 
 
76 → 30 
90 → 44 
106 → 60 
116 → 70 
118 → 72 
120 → 74 
122 → 76 
132 → 86 
132 → 86 
132 → 86 
133 → 87 
134 → 88 
147 → 84 
147 → 84 
148 → 102 
150 → 104 
156 → 110 
166 → 120 
175 → 70 
182 → 136 
204 → 158 
 
1.67 
1.67 
1.70 
1.70 
1.86 
1.95 
1.81 
2.44 
2.53 
2.65 
1.97 
1.78 
1.73 
1.42 
1.77 
2.17 
1.46 
3.71 
1.46 
2.83 
3.14 
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Table S2: Validation results for amino acid quantitation  
 
 
   
 
Sample [µM] 
   
 
Day 1  n 3 
  mean (µM) 9.60 
  RSD (%) 5 
  accuracy (%) 96.0 
    
Day 2  n 3 
  mean (µM) 11.06 
  RSD (%) 11 
  accuracy (%) 110.6 
    
Day 3  n 3 
  mean (µM) 9.51 
  RSD (%) 8 
  accuracy (%) 95.1 
     
     
interday  n 3 
  mean (µM) 10.06 
  RSD (%) 8 
  accuracy (%) 100.6 
     
     
intraday  n 3 
 mean (µM) 9.60 
 RSD (%) 5 
  accuracy (%) 96.0 
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Table S3: Quantitative analysis of NIST peptide solutions (10 µM) by amino acid 
quantitation compared between isotopically labeled amino acid and single amino 
acid; Norleucine as the internal standard 
 
Peptide  Measured Amount (µM) 
Amino acid Stable isotope IST Norleucine as 
IST 
Peptide A  
Alanine 9.2 ± 1.1 9.6 ± 1.0 
Leucine 10.0 ± 0.7 9.5 ± 0.9 
Arginine 9.3 ± 0.9 10.1 ± 0.8 
Mean ± SD 9.5 ± 0.9 9.7 ± 1.0 
Peptide B  
Alanine 10.6 ± 1.5 9.9 ± 1.1 
Valine 9.8 ± 0.7 10.0 ± 0.8 
Leucine 10.5 ± 1.4 10.1 ± 0.9 
Arginine 9.9 ± 0.8 9.6 ± 1.0 
Mean ± SD 10.2 ± 1.1 9.9 ± 1.0 
Peptide C 
Alanine 9.5 ± 0.9 10.3 ± 1.5 
Valine 10.2 ± 1.3 9.6 ± 0.6 
Leucine 10.6 ± 0.6 9.8 ± 0.8 
Arginine 8.9 ± 1.1 9.8 ± 1.4 
Mean ± SD 9.8 ± 1.0 9.9 ± 1.1 
 
a
 The NIST peptide sequences were as flowed: Peptide A sequence: D-A-E-P-D-I-L-E-L-
A-T-G-Y-R Peptide B sequence: K-A-Q-Y-A-R-S-V-L-L-E-K-D-A-E-P-D-I-L-E-L-A-T-G-
Y-R and Peptide C sequence: R-Q-A-K-V-L-L-Y-S-G-R. Amino acids used for 
quantitation are indicated in bold. 
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Table S4: Quantitative analysis of peptide solutions (10 µM) by amino acid 
quantitation 
 
Sample AA used for 
quantitation 
Determined Concentrations 
(µM) 
Sequence 
Sample 1 A,V,L 11.9 ± 1.7 AEEFLNTVVK 
Sample 2 A,V,T,P,D 15.2 ± 1.8 AADEFPQTVVVYYK 
Sample 3 A,T,L,S 9.7 ± 1.4 AEEHLLSSTTK 
Sample 4 A,L,P,D 12.9 ± 1.7 ADEGKLNPSTTVK 
Sample 5 A,L,S,P 12.0 ± 1.6 AAEELPQSK 
Sample 6 V,S 7.7 ± 1.0 GGGSVVWYR 
Sample 7 A,S,P,D 10.4 ± 1.4 AAADDEFGPSTWK 
Sample 8 A,V,S,P,D 9.3 ± 1.2 AADFFNPPSVR 
Sample 9 V,T,D,I 8.8 ± 0.9 DDGHIIQTTVK 
Sample 10 I,S,T 14.7 ± 2.4 EFGGINSSTTK 
Sample 11 A,V,S,L,I 10.4 ± 1.4 AADDGGIILLLPSTVVYK 
Sample 12 A,V,S,P,L 8.2 ± 0.9 ADDLPSSTVK 
Sample 13 P,L,I 10.0 ± 1.4 EEGILLPYK 
Sample 14 V,L 14.5 ± 2.2 EEGKLQTVVK 
Sample 15 V,P,D 9.5 ± 0.7 DDDEFGLPPVYR 
Sample 16 A,V,S,L,I 4.0 ± 1.4 AAAEGGILNSVR 
Sample 17 V,S,P,L 10.2 ± 1.1 EFHLLPSTVK 
Sample 18 T,D,L 6.5 ± 0.8 DEFFLLPQTK 
Sample 19 A,V,S,L 16.5 ± 1.8 ADDDFHLSVYK 
Sample 20 L,S 8.9 ± 1.0 SVNQSLLELHK 
Sample 21 D,L,S 6.4 ± 1.1 DSAFGLLR 
Sample 22 G,A,V,T 11.2 ± 1.5 QGFGNVATNTDGK 
Sample 23 A,S,P,T,L,D 10.4 ± 1.7 SLAPYAQDTQEK 
Sample 24 S,P,V,I,D 9.6 ± 1.5 SPDVINGSPISQK 
Sample 25 A,P,I,L,D 9.6 ± 1.4 EELLPAQDIK 
Sample 26 G,A,T,L 11.0 ± 1.6 TGAQELLR 
Sample 27 A,S,T,D 10.8 ± 1.3 EYTDASFTNR 
Sample 28 A,P,V,T,I,D 9.0 ± 1.4 EIPAWVPFDPAAQITK 
Sample 29 G,A,S,T,L 10.4 ± 1.3 ETAASLLQAGYK 
Sample 30 G,A,L 9.8 ± 0.7 YWGVASFLQK 
Sample 31 V,T,L,D 9.3 ± 1.5 VGDTLNLNLR 
Sample 32 V,T,I,L 9.3 ± 1.1 ITQVLHFTK 
Sample 33 P,V,T,L,D 9.4 ± 1.4 FPEVDVLTK 
Sample 34 G,A,P,T,L 10.2 ± 1.4 LGNQEPGGQTALK 
Sample 35 G,S,T 9.1 ± 0.7 TVGSDTFYSFK 
Sample 36 A,V,L,D 9.2 ± 0.8 ALQDQLVLVAAK 
Sample 37 A,I,L 9.5 ± 1.4 AEIEYLEK 
Sample 38 A,V,T,L 8.8 ± 1.0 LVNEVTEFAK 
Sample 39 A,S,T,L 9.8 ± 1.5 ATEHLSTLSEK 
Sample 40 A,S,P,D 10.4 ± 1.4 AADDTWEPFASGK 
Sample 41 A,S,V 10.6 ± 1.4 NFPSPVDAAFR 
Mean ± SD 
 
10.1 ± 1.3 
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Figure S1: concentration of free amino acids as a function of time of hydrolysis of 
NIST standard peptide B. Hydrolysis was performed and measured in duplicate 
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Figure S2: Representative extracted ion chromatograms for standard peptide 
and  internal standard (isotopically-labeled amino acid and single amino acid; 
Norleucine) 
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Figure S3: Comparison of quantitation using stable isotope-labeled amino acids 
or single amino acid (Norleucine) as the internal standard. NIST peptide B 
solutions (10 µM) were quantified as described using stable isotope-labeled 
amino acids (blue) or norleucine (red) as the internal standard 
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CHAPTER IV 
 
AN IMPROVED METHOD FOR QUANTITATIVE ANALYSIS OF N-TERMINAL 
VALINE ADDUCTS IN ANIMALS EXPOSED TO 1,3-BUTADIENE 
 
Narisa K. Bordeerat, Nadia I. Georgieva, Sujey Carro, Gunnar Boysen, Leonard B. 
Collins, Patricia B. Upton, Vernon E. Walker, James A. Swenberg. 
[Manuscript] 
 
4.1 Abstract 
 1,3-Butadiene (BD) is a well-characterized carcinogen that is both an 
occupational and environmental hazard. It is an important industrial chemical widely 
used in the production of rubber and plastic and is also present in automobile 
exhaust and cigarette smoke. BD is metabolized mainly by P450 2E1 to three 
epoxides, 1,2-epoxybutene (EB), 1,2:3,4-diepoxybutane (DEB) and 3,4-epoxy-1,2-
butanediol (EB-diol). They have the ability to react with hemoglobin in blood. The 
globin adducts formed by EB, DEB, and EB-diol are N-(2-hydroxy-3-buten-1-yl)-
valine (HB-Val), N,N-(2,3-dihydroxy-1,4-butadiyl)-valine (pyr-Val) and 1,2,3-
trihydroxybutyl-valine (THB-Val), respectively.  
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The goal of this research was to develop an improved immnoaffinity UPLC-
positive mode electrospray ionization-tandem mass spectrometry (UPLC-ESI+ -
MS/MS) method for the quantitative analysis of BD N-terminal valine adducts in 
globin extracted from BD-exposed rats. In our approach, N-terminal valine adducts 
are cleaved from globin proteins by trypsin hydrolysis. Following immunoaffinity 
enrichment, samples are subjected to nano-UPLC-MS/MS analysis with 13C15N5-
labeled internal standard peptides. The detection limit of our improved method is 5-
10 fmol in globin (50 mg). This method allowed analysis of globin adducts in rats 
exposed to BD as low as 0.5 ppm via inhalation and demonstrated significant 
differences in the amounts and exposure response in BD epoxide adduct formation. 
The formation of BD epoxide adducts increased with exposure and was most 
efficient with regard to formation per ppm BD at low exposures (0.5-1.5 ppm). The 
amounts of pyr-Val and THB-Val formation saturated at exposures greater than 200 
ppm for 10 days. In contrast, HB-Val concentrations linearly increased with 
exposure. Quantitative methods presented here may be used for studies of biological 
samples in animalsas well as applied to analysis of samples collected from humans 
exposed to BD. 
 
4.2 Introduction 
1,3-Butadiene (BD) is an important  industrial chemical used primarily in the 
production of synthetic rubbers and plastics. The general population is exposed to 
BD from cigarette smoke, burning of wood and automotive exhaust (1–3). 
Epidemiologic studies have linked occupational BD exposure to increased mortality 
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from lymphatic and hematopoietic cancers (4). In long-term (6 h/day, 5 days/week, 2 
years) carcinogenicity studies, inhaled BD was weakly tumorigenic in rats exposed to 
1,000 or 8,000 ppm (5) but was highly effective in mice exposed to BD 
concentrations ranging from 6.25 to 625 ppm (6). Therefore, the International 
Agency for Research on Cancer (IARC) has classified BD as group 1, a human 
carcinogen via inhalation (7). This categorization was based on epidemiologic 
studies and laboratory animal data. BD is a potent carcinogen in mice and 
considerably weaker in rats. In addition, species and gender differences related to 
BD metabolism and DNA repair can be examined by measuring suitable biomarkers 
in order to elucidate the formation of individual epoxides and assign their importance 
in mutagenesis and carcinogenesis.  
Differences are generally related to species-specific metabolic activation to 
reactive epoxy metabolites, mainly 1,2-epoxy-3-butene (EB), 1,2:3,4-diepoxybutane 
(DEB) and 1,2-epoxy-3,4-butanediol (EB-diol). The primary pathways in BD 
metabolism are shown in Figure 4.1. Oxidation of BD by cytochrome P450 results in 
the formation of EB, which can be further oxidized by P450 to DEB. EB and DEB can 
be conjugated with glutathione (GSH) in presence of GSH transferase (GST) and 
can also be hydrolyzed by epoxide hydrolase (EH) to the detoxication pathways 
forming 3,4-dihydroxy-1-butene (B-diol) from EB and EB-diol from DEB. B-diol can 
be oxidized by P450 to EB-diol and by alcohol dehydrogenase to 1-hydroxy-2-
butanone, 1-hydroxy-3-butene-2-one and 2-hydroxy-3-butenal. 
Globin adducts have been widely used as surrogate biomarkers for the 
formation of each epoxide after exposure to chemicals. The globin adduct formed by 
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EB, DEB, and EB-diol are N-(2-hydroxy-3-buten-1-yl)-valine (HB-Val), N,N-(2,3-
dihydroxy-1,4-butadiyl)-valine (pyr-Val) and 1,2,3-trihydroxybutyl-valine (THB-Val), 
respectively (Figure 4.1). Our laboratory has previously developed quantitative 
immunoaffinity (IA) LC-ESI+-MS/MS method for two adducts: the EB-specific adduct, 
HB-Val, and the DEB-specific adduct, pyr-Val, (8, 9). Both types of adducts were 
observed in globin extracted from laboratory animals that were exposed to BD by 
inhalation (9, 10). We have recently used an immunoaffinity ultra pressure liquid 
chromatography-tandem mass spectrometry (UPLC-ESI+-MS/MS) method for 
analysis of pyr-Val (10). This method allowed the measurement of pyr-Val in a wide 
range of BD exposed samples from mice and rats, ranging from concentrations as 
low as 0.1 ppm BD to 1250 ppm BD. However, this current method is not available 
for analysis of THB-Val specific adduct of EB-diol. Furthermore, the application of the 
method is labor intensive requiring extensive sample processing time since the 
analysis of all three adducts can not be measured in a single run. Here, we describe 
the development of a similar method for simultaneous analysis of all three BD 
derived N-terminal valine adducts in the globin of female F344 rats exposed to BD by 
inhalation. 
 
4.3 Materials and Methods 
Materials. Chemical for standard peptides synthesis, Immunoaffinity (IA) 
enrichment, and UPLC-MS/MS analysis 
 Butadiene monoxide (98%) and 1,3-Butadiene diepoxide (97%) were 
purchased from Sigma-Aldrich (St.Louis, MO). 3,4-epoxy-1,2-butanediol was 
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generously provided by Dr. Avram Gold and Dr. Louise M. Ball from the Department 
of Environmental Science and Engineering, University of North Carolina at Chapel 
Hill. The N-terminal alpha chain peptide from rat (VLSADDKTNIK; analyte) and 
([13C155N]-VLSADDKTNIK; internal standard) were synthesized from the peptide 
synthesis facility core at the University of North Carolina at Chapel Hill. Trypsin 
(biotin-agarose from bovine pancrease) was purchased from Sigma-Aldrich. All 
reagents and solvents were ACS grade or higher. Amicon ultra-4 filters were 
obtained from Amicon Inc. (Deerfield, IL). Polyclonal antibodies against all three 
adducts (HB-Val, pyr-Val, and THB-Val) were produced by Anaspec (San Jose, CA). 
The N-terminal alpha chain analyte and internal standard peptides for all three 
adducts were synthesized based on the procedure described below and used for 
antibody production. 
Methods. 
Synthesis of standard peptides 
 Analyte standard peptides, internal standard peptides, and calibration 
standards for tuning the analytical equipment were synthesized as describe below. 
 HB-Val (analyte) and [13C15N5] HB-Val (internal standard) 
 The analyte and stable isotope-labeled rat internal standard peptides were 
synthesized for accurate quantitation by direct alkylation method. The in vitro 
alkylation was done by addition of EB to an aqueous solution of (1-11) peptide at 
molar ratio of 1:100, in 0.1 M ammonium bicarbonate (NH4HCO3) buffer pH 6.5. The 
concentration of the peptides and the pH of the reaction solution were optimized in 
order to increase the reactivity of valine, to minimize the alkylation of lysine, and to 
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minimize the cross-linking of peptides (data from chapter 2). The reaction was 
incubated at 37ºC for 72 h. After incubated, the reaction was stopped with 20% 
formic acid and the pH was adjusted to strong acid condition (pH 2). The yield of 
reaction products was characterized and profiled by LC-ESI+-MS/MS. 
  pyr-Val (analyte) and [2H3] pyr-Val (internal standard) 
 The N-terminal alpha chain standard peptide for pyr-Val in rat and the stable 
isotope (Leu-d3) labeled rat standard peptide were synthesized as described 
previously (11). 
THB-Val (analyte) and [13C15N5] THB-Val (internal standard) 
 The analyte and stable isotope-labeled rat internal standard peptides were 
synthesized by the direct alkylation method, similar to HB-Val standard peptides. The 
in vitro alkylation was done by addition of EB-diol to an aqueous solution of (1-11) rat 
peptide at a molar ratio of 1:20, in 0.1 M ammonium bicarbonate buffer pH 6.5. The 
concentration of the peptides and the pH of the reaction solution were optimized 
(data from chapter 2). The reaction was incubated at 37ºC for 72 h. After incubation, 
the reaction was stopped with 20% formic acid and pH was adjusted to strong acid 
condition (pH 2). The yield of reaction products were characterized and profiled by 
LC-ESI+-MS/MS. 
Animal and Exposures 
 Female F344 rats were exposed by inhalation to 0.1, 0.5, 1, 1.5, 6.25, 62.5, 
200, and 625 ppm BD for 10 days (2 weeks, 5 days/week, and 6 hours/day). The 
exposures were performed at the Lovelace Respiratory Research Institute (LRRI, 
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Albuquerque, NM) as described previously in Georgieva et al. (2010) (10). All animal 
procedures were approved by the LRRI Institute Animal Care and Use committee.  
Globin extraction and trypsin hydrolysis  
 Globin was isolated according the protocol of Mowrer et al. (1986) (12). In 
brief, globin was precipitated by adding 6 volumes of 50 mM of hydrochloric acid in 
isopropanol, followed by centrifugation for 45 min at 3,000 g at 4 oC. The supernatant 
was washed three times with cold ethyl acetate to precipitate globin. The precipitate 
was washed with pentane and dried overnight under a gentle stream of nitrogen gas 
in vacuum oven. The globin was stored at -70oC until use. In sample processing, 
globin samples were digested with trypsin as described previously (9). Briefly, globin 
samples (50 mg) were dissolved in 1-2 ml of 0.1 M NH4HCO3, pH 8 containing 2 
pmol of [2H3] pyr-Val (1-11) peptide, 2 pmol of  [13C15N5] HB-Val, and 10 pmol of 
[13C15N5] THB-Val as internal standard peptides. Ten µl of 10% SDS were added and 
the globin was digested with 50-100 µl of trypsin-biotin agarose enzyme suspension 
at 37oC for 24 h. Samples were filtered through Centricon-3 filters and dried by 
centrifugal lyophilization.  
Immunoaffinity (IA) enrichment 
 After trypsin hydrolysis, the samples were dried and redissolved in 600 µL 
PBS buffer and loaded on immunoaffinity columns that had been pre-conditioned 
twice with PBS. The IA columns were built specifically to retain all three N-terminal 
peptides (HB-Val, pyr-Val, and THB-Val). The columns were capped and left for 4 h, 
washed 5 times with 7 ml of water (5×7 ml), eluted in 5% formic acid (3ml), followed 
by drying under reduced pressure, filtration on microspin filters, and final drying. 
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Samples were stored at -20ºC until analysis and dissolved in 20 µl of water prior to 
nano-UPLC-MS/MS analysis. 
Liquid chromatography mass spectrometry 
 A Thermo-Finnigan TSQ Quantum ultra triple quad mass analyzer 
(ThermoFinnigan, San Jose, CA) interfaced to Water Aquity nano-UPLC system 
(Waters, Milford, MA) was used in all analyses. The system utilized a 2.0 × 20 mm 
Symmetry C18, 5 µm column (Waters) as a “trap column” for samples loading at 15 
µl/min 15 mM ammonium formate-0.7% formic acid for 1 min. After sample loading, 
the flow rate was reduced to 1.2 µl/min and the column exit flow was directed to a 
100 µm × 100–mm BEH C18 UPLC column (Waters) for analysis. The LC solvents 
were 15 mM ammonium formate in 0.7% aqueous formic acid (A) and acetonitrile in 
0.1% aqueous formic acid (B). A linear gradient was run from 5% B to 70% B for 15 
min, at a flow rate of 1.2 µl/min. After elution, the column was washed at 90% B for 
10 minutes and equilibrated at 5% B for 5 min. Under these conditions, all three 
adducts and internal standard eluted within the range 5.9 - 6.1 min.  The MS was 
operated in the positive ion mode with nitrogen used as a sheath gas. Electrospay 
ionization was performed at a spay voltage of 1800 V and capillary temperature of 
240 ºC. Collision induced dissociation (CID) energy was achieved at 28 V. The MS 
parameters were optimized during the infusion of standard peptides solution. 
Method validation 
 Control globins used for validation of matrix effect were obtained from female 
F344 rats. A three-point validation was run on three days (n=3 for each validation 
point for one day, n=9 for each validation point for three days). Validation samples 
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were prepared by spiking control globin with standard peptides. Relative recoveries 
in matrix effects were calculated as the response for all three adducts in a biological 
matrix spiked divided by the actual spiked concentration. The results are reported in 
% recovery for each adduct. The Limits of detection (LOD) were determined by 
signal to noise ration 3:1 based on 5 µl injection volume of calibration standard. The 
lower limit of quantitation (LOQ) was defined as the lowest concentration to be 
detectable from diluted spiking of control globin. The interday and intraday precisions 
were expressed as % relative standard deviation (%RSD) and accuracies were 
expressed as % relative error (%RE).  
Statistical analysis 
All statistic analyses were performed using Microsoft Excel spreadsheet 
analysis tools. Classified precision and accuracy were estimated by simple statistics 
of mean and standard deviation of the estimated concentration of the determined 
peptides. 
 
 
4.4 Results and discussion 
An improved IA-UPLC-MS/MS method 
 It is well known that N-terminal globin adducts are well suited to study BD 
carcinogen metabolism across species (13). Specific globin adducts formed by each 
BD metabolite need to be identified and quantified in order to reveal important insight 
into species, gender, and exposure concentration differences in BD metabolism. We 
have recently demonstrated DEB specific adduct, pyr-Val, in mice and rats exposed 
to BD at different concentrations (10). Since our previous analyses of pyr-Val 
117 
 
adducts was labor intensive and time consuming, the objective of this study was to 
improve the IA UPLC-MS/MS method and simultaneously detect all three globin 
adducts specific for BD metabolites in a single run. We employed the same concept 
as the method for pyr-Val and were able to adapt the method for the analysis of HB-
Val and THB-Val in the concurrent sample. 
 IA columns were produced by combining antibodies raised against all three 
alkylated standard peptides and used for sample purification. Control globin was 
spiked with different amounts of analyte and internal standard peptides to determine 
the reproducibility of IA column. The results showed that the percentage of recovery 
was lower compared to IA columns prepared with individual antibodies. To overcome 
this problem, we adjusted the incubation time on IA columns from 1 h to 4 h at room 
temperature. Using this approach, better recoveries (>70%) were obtained for all 
three adducts (data not shown).  
 The MS was performed in the selected reaction monitoring (SRM) mode by 
monitoring of the singly charged molecular ion (m/z 817→141) for HB-Val, (m/z 
851→175) for THB-Val, and the corresponding transition of the [13C15N5]-label 
internal standard peptide (m/z 823→147) for HB-Val, (m/z 857→181) for THB-Val. At 
the same time, we monitored the doubly charged molecular ion (m/z 417→158) for 
pyr-Val and the corresponding transition of the [2H3]-labeled internal standard 
peptide (m/z 418→158) (Figure 4.2), since this transition presented better sensitivity 
compare to the singly charged molecular ion.  
Quantitative measurement was based on the ratio of area under the peak in 
the selected ion chromatogram corresponding to the analyte and internal standard 
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peptides. Calibration curves were constructed by analyzing the solutions containing 
all three adducts (50 - 500 fmol) and internal standard peptides (500 fmol), followed 
by regression analysis (Figure 4.3). All curves showed a linear response over the 
range of concentrations with a high coefficient of determination (R2= 0.992, R2= 
0.998, and R2= 0.999 for HB-Val, pyr-Val and THB-Val, respectively). 
Method validation 
Limit of detection (LOD) and limit of quantitation (LOQ) 
 LOD was 1 fmol for all three adducts based on 5 µL of injection volume and a 
signal to noise ration of 3:1, while the LOQ was 5 fmol on column for HB-Val and 
pyr-Val and 10 fmol on column for THB-Val. The lower LOQ for THB-Val adducts 
compared to the other two adducts was attributed to the lower signal on ESI+-
MS/MS. This LODs and LOQs allowed detection of all three adducts in rats exposed 
to BD at 0.5 ppm for 10 days. 
 Recovery 
 Relative recovery values for all three adducts in matrix were as follows; 92-
96% for HB-Val, 90-95% for pyr-Val, and 63-73% for THB-Val. The relatively low 
yield of THB-Val was likely due to the low titer of the THB-Val antibody, which may 
have cause less retention during the immunoaffinity purification step. However, 
despite the low yield, our method produced a highly linear calibration curve with 
acceptable precision and accuracy. 
 Accuracy and Precision 
 The method accuracy and precision were determined for three replicates of 
three concentrations of all three adducts. The validated samples were analyzed on 
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three separate days, the interday and intraday precision and accuracy are listed in 
Table 4.1. The RSD of both interday and intraday for all three adducts on the nano-
UPLC-ESI+-MS/MS were below 7% (1.1%-6.6%). The accuracies calculated as 
relative error (RE) were within the range of 2%-6%. The improved quantitation 
method in this study is highly sensitive, accurate, and selective for all three BD 
adducts, allowing the detection of low amounts of adducts in 50 mg globin in rats 
from exposures as low as 0.5 ppm BD. However, the detection of adducts at 0.1 ppm 
BD exposure for 10 days was under the LOQ due to the presence of very small 
amounts of adducts. 
 
Application of the method to BD exposed rats 
Here, we generated a comprehensive exposure response for BD reactive 
epoxides in female rats exposed to BD. F344 rats were exposed by inhalation to 
various concentrations of BD ranging form 0.1 to 625 ppm. In perspective, ambient 
BD concentrations at the work place range form to 0.3 to 3 ppm (14–18). Hence, the 
recently improved quantitative assay allowed analysis of N-terminal valine adducts 
after BD exposures as low as those encountered in occupational environments. The 
data reported herein, demonstrated for the first time the amounts of all three BD 
epoxide globin adducts in female F344 rats. These data will be help understand 
important aspects of BD metabolism, carcinogenesis and mutagenicity.  
 The newly validated quantitative immunoaffinity nano-UPLC-MS/MS method 
was employed to measure the formation of three BD adducts from the same animal 
sample. To test the utility of our method, we determined HB-Val, pyr-Val, and THB-
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Val adducts in each of the globin sample (n = 5/group). Our data (mean ± standard 
deviation) are shown in Table 4.2. The control animals did not contain detectable 
amounts of HB-Val or pyr-Val, suggesting that these adducts are not formed 
endogenously. In contrast, THB-Val (36.8 ± 3.9 pmol/g globin) has been detected in 
control female rats with no exogenous BD exposure as a result of alkylation by 
threose and erythose (19). Representative extracted ion chromatograms for nano-
UPLC-ESI+-MS/MS analysis of all three BD adducts from rats exposed to BD at 6.25 
ppm are shown in Figure 4.2. Even though pyr-Val is the least abundant of the three 
BD adducts quantified, it was 8-fold higher than the method’s LOQ, ensuring 
accurate quantification and presenting excellent signal to noise ratio for the sample 
exposed at 0.5 ppm BD. Therefore, we quantified the formation of the three BD 
adducts in rats exposed to 0.5 - 625 ppm BD for 10 days, in order to obtain data on 
exposure-response relationships. The exposure response curve is shown in Figure 
4.4, and briefly discussed below. 
Exposure response of HB-Val formation 
 We observed a linear exposure-response curve for the HB-Val adducts 
(Figure 4.4). The formation of HB-Val increased with exposure and did not show any 
signs of metabolic saturation at the exposure levels studied. The slope of formation 
was steepest at low exposure (0.5-6.25 ppm) indicating that the rate of formation is 
most efficient at low exposures. These data are consistent with the study by Koc et 
al. (20) where the N7-(2-hydroxy-3-butenyl)-guanine and N7-(1-hydroxy-3-butenyl)-
guanine (N7-HB-Gua), EB-specific N7-guanine adduct has been shown to be linear 
in mice and rats from the lowest exposure studied (20 ppm BD 4 weeks) to high 
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exposures known to induce tumorigenesis (20). Taken together, these results 
confirm that EB metabolism is linearly increased with the exposure.   
The amounts of HB-Val were 40-fold lower compared to THB-Val at 
exposures less than 6.25 ppm and 5 fold lower compared to exposures greater than 
6.25, demonstrating the greater efficiency of metabolism of EB, compared to EB-diol 
at high exposures. HB-Val formed in similar amounts to pyr-Val in female rats at 
exposures less than 200 ppm. However, HB-Val was 2-fold higher at 625 ppm BD 
due to the saturation of pyr-Val formation.  
  
Exposure response of pyr-Val formation 
 The formation of pyr-Val in female F344 rats exposed to BD is plotted in 
Figure 4.4. The amounts of pyr-Val increased with exposure, but with lower 
efficiency shown by decreasing slopes between 1.5 ppm and 6.25 ppm BD. In 
contrast to the linear slope of HB-Val, the pyr-Val response curve reached a plateau 
at  exposures greater than 200 ppm. This suggests that the formation of DEB 
saturates at high exposures in rats, which may saturate the capacity of the P450 
enzymes in the later steps of BD metabolism (10). In addition to reaching a plateau, 
the exposure-response in rats also showed evidence of decreases in slope for pyr-
Val formation similar to our previous observations in the same animals (10). 
  
Exposure response of THB-Val formation 
The exposure response curve for the THB-Val adduct is illustrated in Figure 
4.4. The decreases in slope were observed at concentrations greater than 6.25 ppm 
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BD, showing a supralinear exposure-response curve in the formation of THB-Val 
adducts in female rats. This result suggests that the metabolic activation of BD to 
EB-diol and DEB reach saturation. The amounts of THB-Val adducts were 
approximately 5-40 fold higher than HB-Val and pyr-Val adducts. The saturation 
curve for THB-Val in rats is not surprising, since formation of THB-Gua adducts have 
been shown to reach a plateau at exposures greater than 62.5 ppm BD for 20 days. 
(20, 21). These data are in agreement with the direct comparison of THB-Val to THB-
G adduct formation in animals from the same exposures studied. The EB-diol 
specific DNA adduct (THB-G) was the most abundant and exhibited saturation of 
metabolic activation at 62.5 ppm BD. 
 
4.5 Conclusion 
 In conclusion, we developed a novel immunoaffinity nano-UPLC-ESI+-MS/MS 
combined method for the simultaneous measurement of all three BD-derived 
epoxide N-terminal globin adducts in female rats exposed to BD by inhalation. The 
present method allows selective and sensitive detection of multiple adducts from the 
same sample. In addition, this study is the first report of the measurement all three 
BD adducts using one analysis method in rats exposed to BD. This improved method 
can be further developed to investigate BD globin adduct formation in mice and in 
humans. The current investigation greatly extends our mechanistic knowledge that 
will be important for science-based risk assessment of BD. 
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FIGURES 
 
 
 
 
Figure 4.1 BD metabolism and formation of N-terminal valine adducts 
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Figure 4.2 Ion chromatograms N-terminal valine adducts in F344 rat samples 
exposed to 6.25 ppm 
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Figure 4.3 Calibration curve for N-terminal valine adducts (HB-Val, pyr-Val, and 
THB-Val 
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Dose response curve of BD globin adducts in female rats exposed to BD for 10 days
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Figure 4.4  Exposure response curves of HB-Val, pyr-Val, and THB-Val adducts  
formation in female F344 rats exposed to BD for 10 days 
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TABLES 
 
Table 4.1 Accuracy and precision of IA-nanoUPLC-MS/MS method  
 
 
 
Adduct 
 
Intraday (n=3) 
 
Interday (n=3) 
Conc. 
(µM) 
Determined 
Conc. (µM) 
Precision 
(%RSD) 
Accuracy 
(%RE) 
Conc. 
(µM) 
Determined 
Conc. (µM) 
Precision 
(%RSD) 
Accuracy 
(%RE) 
 
HB-Val 
 
1.0 
 
0.98 ± 0.02 
 
2 
 
2 
 
1.0 
 
0.98 ± 0.07 
 
6.6 
 
2 
 
Pyr-Val 
 
1.0 
 
0.94 ± 0.01 
 
1.1 
 
6 
 
1.0 
 
0.96 ± 0.06 
 
6.6 
 
4 
 
THB-Val 
 
2.0 
 
1.91 ± 0.10 
 
5.1 
 
4.5 
 
2.0 
 
1.88 ± 0.03 
 
1.3 
 
6 
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Table 4.2 Hemoglobin adducts from female rats exposed to butadiene for 10 days 
 
 
Dose (ppm) 
 
HB-Val (pmol/g) 
 
Pyr-Val (pmol/g) 
 
THB-Val (pmol/g) 
0 ND ND 36.8 ± 3.9 
0.1 NQ NQ NQ 
0.5 0.9 ± 0.1 0.8 ± 0.1 2.4 ± 0.3 
1 1.6 ± 0.5 1.4 ± 0.2 29 ± 3 
1.5 2.5 ± 0.4 2.0± 0.5 59 ± 6 
6.25 8.1 ± 0.7 6.7 ± 0.7 220 ± 19 
62.5 60.0 ± 3.0 46.5 ± 8.3 481± 53 
200 148 ± 19 123 ± 8 606 ± 75 
625 410 ± 15 124 ± 11 737 ± 74 
                       ND: not detected, NQ: not quantified 
  Endogenous THB-Val was subtracted in all groups using data from control rats (36.8 pmol/g) 
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5.1 Abstract 
Butadiene (BD) carcinogenicity shows gender, species and concentration 
dependency, making the extrapolation of animal results to humans complex. BD 
is a multi-species multi-site carcinogen, with mice being a much more sensitive 
species than rats. This is considered to be related to the metabolism of BD to its 
epoxy metabolites, 1,2-epoxy-3-butene (EB), 1,2;3,4-diepoxybutane (DEB) and 
1,2-epoxy-butanediol (EB-diol). The mutagenic potency of individual epoxides 
varies up to 200-fold, with DEB being the most mutagenic metabolite. For 
accurate risk assessment it is important to elucidate species differences in the 
internal formation of the individual epoxides in order to assign the relative risks 
associated with their different mutagenic potencies.  
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N-terminal globin adducts have been widely used for measurements of the 
formation of BD derived epoxides. In this study, the internal adduct dose of each of 
the epoxides was evaluated in globin samples from both genders of mice and rats 
exposed to BD from 0.1 to 625 ppm by inhalation for 10 days. The number of globin 
adducts was then converted into EB dose equivalents. These were calculated on the 
basis of the combined internal dose (globin adducts) and the relative genotoxic 
potency of the respective epoxides inferred from the efficiency of inducing mutations 
at the Hprt locus. Then, the multiplicative cancer risk model was applied to 
quantitatively estimate tumor incidence by using the EB dose equivalent and long-
term cancer bioassy data. Based on the EB dose equivalent, higher exposures 
formed lower amounts per ppm BD. This indicates that metabolism of BD to 
epoxides is most effective at low exposures (0.5-1.5 ppm). The EB equivalent for 
mice was about 40-fold higher than that of rats at same exposures levels. No gender 
differences were noted in globin adducts of mice or rats at all exposures. Predicted 
tumor incidences from the cancer risk model correlated well with the earlier observed 
tumor incidences in cancer test. As such, EB dose equivalents provide quantitative 
data on biomarkers of exposure that can be extended to a scientific basis for BD risk 
assessment. 
 
 
5.2 Introduction 
1,3-Butadiene (BD) is a high-volume industrial chemical used in the 
production of plastics and rubber (1). It is also an environmental pollutant present in 
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automobile exhaust and cigarette smoke (2, 3). BD is classified as a human 
carcinogen based on laboratory animal data linking it to the formation of cancer. 
Human epidemiology data are revealing increased incidences of leukemia and 
lymphohematopoietic cancer in workers occupationally exposed to BD. Genotoxicity 
data derived from laboratory animal studies demonstrated the induction of point 
mutations, large deletions, and chromosomal aberrations following exposure to BD 
(4– 8).  
Bioactivation to yield reactive epoxides of BD in animal and human tissues 
has been suggested to be an important determinant of the mutagenic and 
carcinogenic effects of BD (9).  BD is metabolized by cytochrome P450, forming 
reactive epoxides: 1,2-epoxybutene (EB), 1,2:3,4-diepoxybutane (DEB) and 3,4-
epoxy-1,2-butanediol (EB-diol) (10).  Of critical importance is the fact that BD-derived 
epoxides differ in their mutagenic potencies by up to 200-fold, with DEB being the 
most potent mutagenic metabolite due to its capacity as a bifunctional electrophile 
(11, 12). All three epoxides are known to form DNA and protein adducts. EB 
produces N-(2-hydroxy-3-buten-1-yl)-valine (HB-Val), and DEB forms N,N-(2,3-
dihydroxy-1,4-butadiyl)-valine (pyr-Val) and 1,2,3-trihydroxybutyl-valine (THB-Val). 
The later adduct is also formed from EB-diol and is present in unexposed animals 
and humans from endogenous sources. A simplified pathway for metabolic and 
globin adduct formation of BD is shown in Figure 5.1  
BD inhalation cancer studies in mice and rats revealed that it was 
carcinogenic in both species, but with a striking difference in sensitivity and tissue 
specificity. Mice developed tumors following exposures as low as 6.25 ppm BD (7), 
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Rat were studied at 0, 1000, 8000 ppm BD and no lower exposure levels were tested 
for carcinogenicity. Tumors were observed at the exposure reached 1,000 ppm BD 
(13). Furthermore, the target tissues for BD-induced cancer in mice (lung, heart, and 
hematopoietic system) were different from those in rats (thyroid, pancreas, testis, 
and uterus) (8). Therefore, BD is a potent carcinogen in mice and considerably 
weaker in rats. The increased susceptibility of mice to the carcinogenicity of BD may 
result from a more efficient metabolic activation of BD in this species (11). Mice 
formed 10- to 60-fold more pyr-Val compared to rats at similar exposures (14). In 
addition, concentrations of racemic bis-N7G-BD, a DEB specific DNA cross-link, 
were 4- to 10-fold higher in mice than in rats at all exposure levels. (15). These 
studies provide a possible explanation for the strong tumorigenic response to BD in 
mice. 
 We have recently developed a quantitative ultra-performance liquid 
chromatography-electrospray ionization-tandem mass spectrometry (UPLC-ESI+-
MS/MS) method for quantifying pyr-Val and HB-Val adducts (14, 16). In our 
approach, the N-terminal valine adducts are released from the globin chain by 
trypsin hydrolysis, enriched by immunoaffinity chromatographic (IA) and analyzed by 
nano UPLC-ESI-MS/MS using the corresponding [13C155N]-labeled adducts as 
internal standards. Using nano-UPLC-MS allowed analysis of pyr-Val in mice and 
rats exposed to BD as low as 0.1 and 0.5 ppm BD, respectively, and demonstrated 
significant differences in the amounts of pyr-Val formed. The study analyzed pyr-Val 
in rodent tissues in an attempt to explain the observed interspecies differences in 
carcinogenic response. We observed that the lower susceptibility of rats to BD-
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induced carcinogenesis due to greatly reduced formation of DEB following exposure 
to BD. Additional data for HB-Val and THB-Val adduct formation are needed to better 
understand the species susceptibility and dose dependence of BD mutagenesis and 
carcinogenesis. 
 Research has shown that BD is genotoxic in rodents. Differences in Hprt Mf 
were significantly higher in both species when exposed to 1250 ppm BD for 2 weeks 
compared to controls (3.5-fold, rats/control) (9). The lowest exposure to BD that 
produced a significant increase in Hprt Mf was 3 ppm in mice and 62.5 ppm in rats 
(9). Since DEB has been shown to be a much more potent inducer of mutations than 
EB and EB-diol, the interspecies difference in the potency of genotoxic effects may 
be related to the differences in the rate of formation and detoxification of DEB (14). 
Recent in vitro studies have exposed TK6 cells to nine different stereochemical 
configurations of BD epoxides and assayed them by multiplex PCR for both Hprt and 
TK genes (17). These studies demonstrated that the mutagenic potency of EB was 
100-fold less than the average equimolar effect of DEB, and was 5-fold greater than 
the average equimolar effect of EB-diol. In addition, marked differences were 
observed in cytotoxicity and mutagenicity among the four stereoisomers of EB-diol. 
(2R,3S)-EB-diol was the most mutagenic monoepoxide stereoisomer, being 30 times 
more mutagenic than the other 3 forms of EB-diol and 5-10-fold less mutagenic than 
DEB (17). 
 Cancer risk estimation on the basis of the internal dose of genotoxic 
chemicals represents an important factor for the assessment of cancer risk. An 
improved approach for risk estimation, the multiplicative risk model, is being 
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developed based on experiences from studies of ionizing radiation (18, 19). 
Evaluations of animal cancer tests using this approach indicate that a multiplicative 
cancer risk model could be applied to genotoxic chemicals (20). Accordingly, the 
cancer risk increment is proportional to the internal dose of the causative genotoxic 
agent, and its genotoxic potency specific for the studied species, strain and gender. 
In addition, the relative risk increment, according to this model, is common for 
different responding sites. Therefore, the model has been shown to provide a way of 
predicting tumor incidence in animal cancer tests with genotoxic agents. This model 
can be used for extrapolation to human cancer risk, giving an approximate risk 
coefficient for different species (19). Moreover, the applicability of the multiplicative 
risk model to cancer test data for ethylene oxide (20), acrylamide (21), and 1,3-
butadiene (22) has been evaluated. It has been shown that the internal dose of the 
genotoxic agent and the observed tumor incidence in animal cancer tests are well 
correlated with the predicted incidences from the multiplicative risk model. 
Furthermore, the model can be applied to genotoxic agents and is useful for the 
interspecies extrapolation. The major factor that is not incorporated into this model is 
the role of endogenous DNA damage in determining low dose risk assessments (23, 
24). 
A dose concept for genotoxic electrophiles has been developed where the 
dose is defined as the time integral of the concentration of the genotoxic compound, 
which is the same as the “area under the concentration-time curve” (AUC). For the 
purpose of internal dosimetry of the genotoxic chemical, the internal dose of the 
reactive epoxide metabolites, EB, DEB, and EB-diol will be calculated from the 
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measurement of globin adducts at the N-terminal site using immunoaffinity UPLC-
MS/MS method. While endogenous THB-Val is formed, no endogenous BD DNA 
adducts are formed, making this data set appropriate for the risk assessment model. 
The evaluation of BD cancer studies is a challenge because of large species 
differences in sensitivity, and because all three epoxide metabolites are genotoxic 
and may contribute to tumor formation. Therefore, this study provides a 
comprehensive data set for the exposure-response of globin adduct formation due to 
BD-derived reactive epoxides in male and female mice and rats exposed to various 
concentrations of BD by inhalation. Exposures ranged from 0.1 to 625 ppm BD for 10 
days. The multiplicative risk model is then used to assess the BD cancer bioassay 
data and internal adduct doses. 
 
5.3 Materials and Methods 
Long-term inhalation exposure to BD in cancer bioassays 
 Data from two chronic cancer bioassays that used inhalation of BD in 
Sprague-Dawley rats and B6C3F1 mice are used for the evaluations in this study (13, 
25). The animals were treated for 6 h per day, 5 days per week for approximately 2 
years. Duration of exposures for the different groups were: 3090 h (female and male 
mice), 3150 h (female rats) and 3330 h (male rats). Five groups of 50 mice were 
exposed to 0, 6.25, 20, 62.5, 200, or 625 ppm BD and three groups of 100 rats were 
exposed to 0, 1000, or 8000 ppm BD. All exposure doses and all tissues showing a 
significant response in the cancer bioassays, as reported in the review of NTP (25), 
were used in the evaluation. Since the BD exposures in the carcinogenicity bioassay 
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in mice were matched with that of the animals in the globin adducts study, only data 
from mice were applied to the multiplicative model. Table 5.1 summarizes the target 
organs and types of neoplasia observed. 
 
Animals and exposures in globin adducts studies 
 The exposures were performed at the Lovelace Respiratory Research 
Institute (Albuquerque, NM) according to protocols approved by the Institutional 
Animal Care and Use Committee. B6C3F1 mice (male and female) and F344 rats 
(male and female) were exposed by inhalation to 0.1, 0.5, 1, 1.5, 6.25, 62.5, 200, or 
625 ppm BD for 10 days (2 weeks, 5 day/week, and 6 h/day). At the end of the last 
exposure, animals were killed by exsanguination under CO2 anesthesia and blood 
samples were collected by cardiac puncture within 2 h of the last exposure. Red 
blood cells were isolated, washed twice with 0.9% saline, diluted 2× in distilled water, 
and stored at −80°C before extraction of globin.  
 
Analysis of Hemoglobin adducts 
 Globin sample processing 
 Globin adducts from BD derived reactive epoxides were quantified by 
measuring, HB-Val, pyr-Val, and THB-Val based on an improved IA-UPLC-MS/MS 
method using peptide standards that had been quantified accurately as described 
by Bordeerat et al.(2009) (26).  In brief, globin isolation was performed according 
to Mowrer et al. (1986) (27). Globin samples of 10–50 mg (depending on the species 
and the exposures) were dissolved in 1.5 ml of 0.1 M NH4HCO3 and 2 pmol of [2H3] 
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pyr-Val, 2 mol [13C15N5] HB-Val, and 10 mol [13C15N5] THB-Val internal standard (1–
11) peptide were added. Samples were digested for 24 h at 37°C with 50–100 µl of 
trypsin-biotin-agarose suspension (washed in advance twice with 0.1 M NH4HCO3). 
After Centricon-3 filtration, samples were dried and redissolved in 600-µl PBS buffer, 
loaded on IA columns, and left capped for 4 h. After extensive washing with distilled 
water (5 × 7 ml) and elution in 3 ml of 5% formic acid, followed by sample drying, 
filtration on Microspin filters, and final drying, samples were stored at −20°C until 
analysis by nano-ultra high pressure liquid chromatography-tandem-mass 
spectrometry (nano-UPLC-MS/MS). 
 
 Liquid chromatography and mass spectrometry analysis 
 The quantitative analysis of the globin adducts from BD derived reactive 
epoxides by nano-LC-MS/MS was performed with a nano-UPLC (Waters, Milford, 
MA) coupled to a TSQ-Quantum Ultra triple quad mass analyzer (ThermoFinnigan, 
San Jose, CA). The system utilized a 2.0 × 20 mm Symmetry C18, 5 µm column 
(Waters) as a “trap column” for samples loading at 15 µl/min 15 mM ammonium 
formate-0.7% formic acid for 1 min. After sample loading, the flow rate was reduced 
to 1.2 µl/min and the column exit flow was directed to a 100 µm × 100–mm BEH C18 
UPLC column (Waters) for analysis. A linear gradient was run from 5% 
acetonitrile/15 mM ammonium formate in 0.7% aqueous formic acid for 5 min then to 
70% acetonitrile/15 mM ammonium formate in 0.7% aqueous formic acid for 10 min 
at a flow rate of 1.2 µl/min. Under these conditions, all three adducts and internal 
standard eluted within the range 5.9 - 6.1 min. The retention times for the analyte 
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and internal standard were determined with authentic standards, and all adducts in 
the sample were detected in selected reaction monitoring mode. The electrospray 
conditions were spray voltage of 1800 V and capillary temperature of 240°C. 
Collision energy was 28 V. 
 
Calculation of internal adduct dose from levels of Hemoglobin (Hb) adducts  
The internal adduct dose (D; in mMh·ppmh-1) was calculated from the 
measured number of Hb adducts (A; in mol·g-1) and the reaction rate constant of the 
electrophilic agent towards the nucleophile, kval in [L·g-1·h-1] as shown in Equation 1.  
 
(Equ. 1)    D = (1×A)÷ kval 
 
 
In situations when A is measured after a period of exposure (10 days), the life 
span of erythrocytes (ter) has to be considered for adjustment of the accumulation 
and disappearance of Hb adducts. The number of accumulated adducts (Acc) is 
related to the daily adduct increment (a) according to Equation 2. The ter values 
used were 40 days for mouse (28) and 60 days for rat (29). 
 
(Equ. 2)   at t < ter;  Acc = a × t (1- t/2ter) 
 
The rate constant for the reaction of the epoxy metabolites of BD were used 
as reported in Fred et al. (2008) (22). The different values of kval used in calculations 
for each epoxide were as follows: EB 4.0×10-5 L·g-1·h-1, DEB 5.5×10-5 L·g-1·h-1 and 
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EB-diol 2.3×10-5 L·g-1·h-1 for rat; EB 2.9×10-5 L·g-1·h-1, DEB 4.7×10-5 L·g-1·h-1 and EB-
diol 2.1×10-5 L·g-1·h-1 for mouse.  
 
Calculation of EB dose equivalent 
 The D of the genotoxic and potential cancer-initiating agent is one parameter 
in the multiplicative risk model (20). The cancer bioassay results for BD have to be 
evaluated with regard to the D of the genotoxic epoxide metabolites (EB, DEB and 
EB-diol) at different exposures. Moreover, the differences in the mutagenic potency 
of the epoxides have to be considered.   
 In a study using human TK6 cells it was shown that EB, DEB, and EB-diol 
were effective at inducing mutations in Hprt loci. Meng et al. (17) reported that the 
initial treatment concentrations of individual epoxides inducing a doubling of the 
mutation frequency were 200 µM, 2 µM, and 1,000 µM for EB, DEB and EB-diol, 
respectively. We used this reference as our estimate for the relative mutagenic 
potencies, with EB as a reference having a value of 1, DEB having a value of 100 
and EB-diol having a value of 0.2. The EB dose equivalent was then calculated by 
multiplying the internal hemoglobin adduct dose (D) of the respective epoxide with 
the corresponding mutagenic potency (Equation 3). 
 
(Equ. 3)       Dose-equivalent = DEB × 1 + DDEB × 100 + DEB-diol × 0.2  
 
 Equation 3 is expressed as EB dose equivalents (nMh) per exposure dose of 
BD (ppmh). 
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Application to multiplicative risk model 
 This model known as the excess relative risk model, often applied in radiation 
research, was fitted to the tumor incidence data. The model implies that the fraction 
of animals with tumors in target tissue (i), i.e. Pi(D), can be described by the 
following equation: 
 
(Equ. 4)       Pi(D) = 1 –  e-Piº (1+ßD) 
 
 
 D denotes the EB-equivalent dose in target tissue. In the present evaluation of 
cancer bioassays for BD, the dose denotes the total dose in the blood of the 
genotoxic BD epoxides. For specific organs the dose in the blood has to be related 
to target dose. Pi0 represent the cumulative hazard for tumor formation in the target 
tissue. i represent tumor incidence among unexposed animals. ß is the common 
relative excess risk per unit of dose. 
 The parameters of this nonlinear function were estimated by a binomial 
regression model with 95% confidence intervals. The fit of the model is presented as 
observed versus predicted tumor incidence. 
 
5.4 Results and discussion 
N-terminal valine globin adducts in rodents exposed to BD 
 N-terminal hemoglobin adducts have been used as markers for BD exposure 
and the formation of individual epoxides in rodent models. These studies are critical 
for understanding the mechanisms of BD carcinogenesis and mutagenesis, because 
the epoxides exhibit significantly different mutagenicity. Although analyses of pyr-Val 
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in a previous report (14) have greatly enhanced our knowledge of BD metabolism 
across species, information on HB-Val and THB-Val formation are needed to provide 
better understanding of species, gender and concentration dependencies in BD 
metabolism. This report describes the first analysis of all three BD-derived epoxide 
adducts bound at N-terminal valine  in mice and rats after 1BD inhalation exposure 
at concentrations ranging from those known to induce tumors in rodents and to those 
approaching human occupational exposures. Hemoglobin adducts from rats and 
mice exposed to butadiene for 10 days are given in Tables 5.2 and Tables 5.3, 
respectively. 
 HB-Val adducts in rats and mice 
 The first step in BD metabolism is oxidation by P450 2E1 to EB, which forms 
the HB-Val adduct. Using nano-UPLC-MS/MS increased sensitivity and allowed 
detection of HB-Val in mice and rats exposed to BD as low as 0.1 and 0.5 ppm, 
respectively. The amounts of HB-Val in rats exposed to 0.1 ppm were below the limit 
of detection. The exposure-responses of HB-Val formation in F344 rats and B6C3F1 
mice are plotted in Figure 5.2. After 10 days of exposure, female mice formed 10 ± 
4.4 more EB, measured as HB-Val formation, than rats at same exposure 
levels. Thus, mice were shown to be more efficient in EB formation than rats, 
providing insight into possible mechanisms responsible for the observed species 
differences in tumor susceptibility. The formation of HB-Val in mice and rats 
increased with exposure, exhibiting curvilinear dose response curves with no 
evidence of metabolic saturation. (Figure 5.2) These data are in agreement with the 
study by Troutman et. al. (unpublished data) where the EB specific DNA adduct N-7-
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(2-hydroxy-3-buten-1-yl)guanine (HB-G I), and N-7-(1-hydroxy-3-buten-2-yl)guanine 
(HB-G II) formation in the liver were shown to be curvilinear in the same group of 
mice exposed to BD for 10 days. 
pyr-Val adducts in rats and mice 
 The reaction of DEB with Hb produces an N-terminal valine adduct that 
undergoes an intra-molecular ring closing reaction to form the pyrolidine adduct, pyr-
Val (30). Cross-linking with other Hb sites and hydrolysis to THB-Val have also been 
reported; however, they are minor products compared to pyr-Val formation (31). To 
examine the formation of pyr-Val, we used a nanospray-UPLC-MS/MS approach. 
Similar to HB-Val, this method allowed the detection of pyr-Val in mice and rats 
exposed to BD as low as 0.1 and 0.5 ppm, respectively. The exposure-responses 
of pyr-Val formation in F344 rats and B6C3F1 mice are plotted in Figure 5.3. The 
formation of pyr-Val in female mice increased with exposure, and the slopes of 
formation in mice was steepest at exposures ≤ 1.5 ppm (Figure 5.3 insert). In 
female rats exposed for 10 days, progressive decreases in the slope of formation 
of pyr-Val were found at exposures between 1.5 and 62.5 ppm BD with a plateau in 
formation observed at exposures to 200 ppm BD and above (Figure 5.3). The 
presented exposure-response curves for pyr-Val clearly establish a change in the 
slope at exposures below 1.5 and 6.25 ppm in mice and rats, respectively (see 
inserts in Figure 5.3). In mice, exposures below 1.5 ppm BD produced about 26 
pmol/g globin/ppm BD, while at exposures greater than 1.5 ppm, this rate decreased 
as much as 10-fold at higher exposures, reaching 2.5 pmol/g globin/ppm BD at 625 
ppm. These data demonstrate that formation of pyr-Val is highest at low exposures 
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(0.5-1.5 ppm). The exposure-response curve reached a plateau in rats at exposures 
of 200 ppm or greater, providing evidence for the saturation of metabolic activation 
pathways in rats. In addition, mice formed 10 ± 2.9 more DEB than rats at similar 
exposures. These data confirm that mice form much higher amounts of pyr-Val than 
rats, suggesting metabolic differences as a cause for the species differences in 
cancer susceptibility. 
THB-Val adducts in rats and mice 
 THB-Val is primarily formed from EB-diol, however, small amounts can be 
formed by one of the epoxy groups of DEB binding to the N-terminal valine, followed 
by hydrolysis (31). THB-Val in several species, including rats, mice, monkeys, 
horses, dogs, and humans has been detected without exogenous BD exposure. The 
source of this endogenous THB-Val remains unknown, but some studies suggest it 
may arise from the alkylation reactions of threose and erythose (32). The exposure 
response curve for THB-Val adduct in F344 rats and B6C3F1 mice is illustrated in 
Figure 5.4. The formation of THB-Val in mice increased with exposure, and the 
slopes of formation in mice were steepest at exposures ≤ 6.25 ppm (Figure 5.4 
insert). The exposure-response curves were linear and did not show any signs of 
metabolic saturation. In contrast to mice, the exposure-response curve in rats was 
supralinear and decreased in slope at greater than 6.25 ppm BD. This result 
suggested the metabolic activation of BD to EB-diol becomes less efficient as the 
exposure increases. 
The amounts of THB-Val adducts were approximately 5–40-fold higher than 
HB-Val and pyr-Val adducts in both rats and mice. These data are in agreement with 
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the direct comparison of THB-Val to THB-G adduct formation in mouse tissue from 
the same exposures studied by Troutman et. al. (unpublished data). The EB-diol 
specific DNA adduct (THB-G) was the most abundant and exhibited supralinear 
metabolic activation at 6.25 ppm BD. 
 
Species differences in globin adduct formation 
 The data presented suggest that species differences observed in globin 
adduct formation are directly related to differences in the extent of BD metabolism to 
its epoxides. BD has been shown to be a potent carcinogen in mice, inducing 
neoplasms at multiple sites. In contrast, rats were less susceptible, developing 
neoplasms only at high BD concentration. The data from long term studies in mice 
and rats are in agreement with the studies on globin adduct formation. Determination 
of all three adducts (HB-Val, pyr-Val, and THB-Val) in rodents demonstrated that 
mice form much higher amounts of the adducts (6–10- fold) than rats under identical 
exposure conditions ranging from 0.1 – 6.25 ppm BD. The data from this study point 
to DEB as the key metabolite, producing the observed species diversity in BD 
susceptibility. The formation of pyr-Val increases with exposure in mice and 
saturates in rats at exposures greater than 200 ppm BD, clearly demonstrating 
different kinetics in DEB formation. These findings are consistent with in vitro 
metabolism data from Filser et al. (2007), reporting higher amounts of DEB formation 
in mice compared to rats after EB exposure (33). Furthermore, these data are in 
agreement with the study of Walker and Meng et al. (34-35), demonstrating greater 
formation and potentially increased mutagenicity of DEB in mice compared to rats. 
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Gender differences  
Multiple BD studies have revealed gender differences in the development of 
neoplasia, Hprt, and amounts of DNA-DNA cross-links formed. Mutagenicity studies 
measuring BD-induced Hprt gene mutations in mice and rats have demonstrated 
gender differences in sensitivity, with rat and mouse females having 2.3–3-fold 
greater Hprt Mfs than their male counterparts (9, 36). Furthermore, Thornton-
Manning et al. (1997) reported an approximately 6-fold greater formation of DEB in 
the blood of female mice after a single 6 h inhalation exposure (37). 
By comparison, female rats and mice had more bis-N7G-BD, racemic and 
meso DNA-DNA cross-links  than males at high exposures (200 ppm and 625 ppm) 
(15). However, our study showed no significant gender differences for the three BD 
epoxide adducts at the exposure concentrations studied in both rats and mice 
(Figure 5.5a and Figure 5.5b). In addition, there were no gender differences in the 
amount of N-7 guanine monoadducts in mice. HB-G and THB-G indicate that there is 
no difference in BD metabolism in female and male rats and mice at multiple 
exposure concentrations and durations (Troutman et. al.; unpublished data). This 
comprehensive data set strongly suggests that a deficiency in DNA cross-link repair 
in females is the most plausible hypothesis for the gender differences in mutagenic 
and carcinogenic susceptibility. 
 
Internal adduct dose and EB dose equivalent 
 The present globin adduct data provide valuable insight into cross-species 
comparisons and represents the most comprehensive data set available for mice 
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and rats. The internal adduct dose of epoxy metabolites of BD (D; in nMh·ppmh-1) 
was calculated from the measured Hb adducts level (A; in mol·g-1). These were then 
used to calculate the total genotoxic dose, express as EB dose equivalent (DEB), 
considering the genotoxic potency of the individual epoxide metabolites. The internal 
adduct doses of all three epoxy metabolites of BD, and the EB dose equivalents for 
mice and rats are presented in Table 5.3. Generally, the internal adduct dose of the 
epoxide metabolites decreased with exposure (per ppmh) in both mouse and rat. For 
all three epoxides the highest internal adduct doses per exposure dose were 
observed at 0.5 ppm. This indicates a more effective metabolism to epoxides at 
lower exposure levels. A predominant difference between the mouse and the rat was 
observed with regard to the internal adduct dose of DEB, which was higher in the 
mouse than the rat by about 30 – 50 times. In addition, the internal dose of DEB in 
the rat showed saturation at 200 ppm and above. The species differences in DEB 
formation represent the major cause of the dissimilarity in the calculated EB dose 
equivalent.  
Based on the EB dose-equivalent, the highest dose per ppm exposure was 
observed at sub-part per million exposures. This demonstrates that metabolism of 
BD to epoxides is most effective at low exposures. Comparing the EB dose-
equivalents between species, mice clearly differ from rats, being ~30 times greater at 
similar exposures. A quantitative difference in metabolism between the two species 
suggests that DEB is the major contributor to the EB dose equivalent in the mouse, 
while in the rat DEB represents a minor fraction of the EB dose equivalent. 
Therefore, it may be concluded that DEB is the predominant cause of tumor 
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formation in mouse, and EB together with EB-diol are the causative agents in the rat. 
This provides important information relevant to susceptibility issues and species 
differences for BD.  
 
Relative genotoxic potency 
 In the present study the relative in vitro mutagenic potencies of the three 
epoxide metabolites were used to calculate the EB dose equivalent from internal 
adduct doses of epoxides. The EB dose equivalent was then applied as a parameter 
in a multiplicative risk model.   The estimations of mutagenic potencies of the 
epoxides were calculated from the initial treatment concentration of individual 
epoxides inducing a doubling of the mutation frequency in Hprt loci of human TK6 
cells. This procedure might be associated with potential bias, since the relative 
genotoxic potencies were estimate from in vitro data. It would have been desirable to 
perform in vivo mutation tests in parallel with internal adduct dose measurements of 
the reactive metabolites, but these data are not available. However, the observed 
mutation frequency of BD and 3-butene-1,2-diol (B-diol), a precursor of EB-diol, in 
rodent samples (9) is in agreement with the estimated relative mutagenic potency as 
used in the present study. 
 
EB dose equivalent and mutagenic efficiency 
 Direct comparisons of EB dose equivalent to mutagenic efficiency in female 
mice can be made, since animals from the same exposure have been studied. 
Walker and Meng et al. determined the Hprt mutant frequencies in T-cells from mice 
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after 10 days of inhalation exposures to 3, 20, 62.5, 200, and 625 ppm BD (9, 38). 
The induction of Hprt mutations in T lymphocytes in BD exposed mice was highest at 
the lowest exposure (3 ppm BD), similar to the EB dose equivalent. These data 
demonstrate that metabolism of BD to epoxides and BD mutagenic efficiency are 
most effective at low exposures. The shape of the dose–response curve for the EB 
dose equivalent was very similar to the shape of the dose–response curve for the 
induction of Hprt mutations in T lymphocytes in BD exposed mice (Figure 5.6). The 
figure demonstrates that EB dose equivalent and the induction of Hprt mutations 
drops rapidly between 3 and 62.5 ppm BD. Comparison between the biomarker of 
exposure (EB dose equivalent) and biomarker of effect (Hprt mutant frequency) were 
highly correlated (r2=0.97) (Figure 5.7). Additional analyses are needed to fill gaps in 
the EB dose equivalent and Hprt mutant frequency data for male mice and both 
genders of rats. However, these data in female mice suggest that EB dose 
equivalent can be a highly predictive biomarker for BD-induced mutations and 
cancer risk. 
 
Multiplicative cancer risk model 
   The EB dose equivalents obtained in the short-term exposure to BD were 
used to quantitatively estimate the percentage of tumor incidence in the long-term 
BD cancer test. In this study according to the multiplicative risk model, the data for 
sites with significant response were evaluated together, that is, all sites, doses, and 
genders. The survival-adjusted neoplasm rates for B6C3F1 mice used for fitting the 
model are presented in Table 5.1. The long-term cancer test data from F344 rats 
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were not evaluated in this study, since the BD exposure levels were higher (1000 
ppm and 8000 ppm) than the short-term experimental data available, and lower 
exposures have not been tested for carcinogenicity. 
 The fit of the model (equ.3) was displayed as the relationship between the 
percentages of observed and predicted numbers of animals with tumors at any target 
site (Figure 5.8). The goodness of fit of the model demonstrated a significant 
correlation (p < 0.001) between observed tumor incidence and predicted values 
based on internal adduct doses. In addition, the quantitative estimations of the 
percentage tumor incidence specific for each BD exposure level in male and female 
mice are shown in the Figures 5.9 and 5.10, respectively. The percentage of tumor 
incidence increased with exposure as follows: 5% for 200 ppm BD, 15% for 625 ppm 
BD in male mice; and 4% for 6.25 ppm BD, 15% for 62.5 ppm BD, 15% for 200 ppm 
BD, 22% for 625 ppm BD in female mice. This approach can be applied to genotoxic 
agents (or metabolites) when doses in the target tissue can be estimated. The model 
provides a reasonable result for applying internal adduct doses in estimation of 
tumor incidence from long-term inhalation exposure to BD.  
 There is some potential bias in our study. The inclusion of all target sites 
showing a significant increase in tumor incidence may lead to an over-estimation of 
the relative potency since the spontaneous lymphomas of aging B6C3F1 mice were 
observed and included in all exposure groups. The second source of bias is related 
to the fact that exposure decreases the overall survival. Exposure-related mortalities 
first occurred during week 23, mainly in mice exposed to 625 ppm, and were due 
primarily to the induction of fatal neoplasms and their associated lesions.  No female 
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mice exposed to 200 and 625 ppm or male mice exposed to 625 ppm survived to the 
end of the study. Survival decreased for males and females exposed to 
concentrations of 20 ppm or above. The decrease in survival was dose related. 
However, this problem has been corrected using the survival-adjusted neoplasm 
percentage as a parameter for fitting the model. 
 
Application of measurements of butadiene hemoglobin adducts in occupationally 
exposed workers 
 The utility of hemoglobin adducts of BD was investigated in molecular 
epidemiology studies by Hayes et al. (39) and Albertini et al. (40). The Hayes et al. 
study examined workers in a BD latex plant for the urinary metabolite (M-1 
mercapturic acid butanediol formation), THB-Val, hprt mutations, sister chromatid 
exchanges (SCE), glycophorin A mutations and chromosomal aberrations. THB-Val 
showed a significant correlation (Spearman's ρ = 0.40, P = 0.03) with exposure to 
butadiene, which averaged 1–3 ppm for exposed workers. Urinary M-1 metabolites 
were also correlated with exposure. None of the genetic toxicity endpoints exhibited 
any increase in exposed individuals compared to the unexposed. The results 
indicate that THB-Val is a useful biomarker of biologically effective dose.  
The Albertini et al. study was the first to examine both THB-Val and HB-Val. 
This study had extensive industrial hygiene measurements of BD exposures in the 
work environment, including individual breathing-zone monitoring during 60 
workdays. THB-Val exhibited excellent correlation with exposure responses (r2 = 
0.74). Biomarkers for genotoxicity were examined and no increases were associated 
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with BD exposure. While both hemoglobin adducts and urinary metabolites were 
good surrogates for exposure, genotoxicity endpoints had no correlation with 
exposure (40) 
 Recent BD exposure-biomarker study by Swenberg et al. presented the 
comprehensive data set available for the three species (rat, mouse, and human) 
(41). The average air exposures in human studies were 0.29 ppm and 0.81 ppm in 
monomer workers and polymer workers, respectively. In rodents, the exposures 
were 0.5 -625 ppm BD for 10 days.  The period of exposure in humans was 5.3 
times longer than in the rodent studies. Comparing the internal hemoglobin-adducts 
dose between the three species, the rat approves to be a more representative 
animal model to study human effects following BD exposure than the mouse. 
Surprisingly, EB-diol approves to pose the greatest risk for mutations in humans. 
This provides important information relevant to susceptibility issues and species 
differences in BD exposure assessment. 
 Smoking is considered to be an important confounder in occupationally 
exposed workers. The BD-intake caused by smoking can be calculated assuming 
3.5 ppm BD/cigarette for mainstream smoke (42). Accordingly, the median 
exposure level of 14 ppm BD corresponds to smoking of about 3–4 cigarettes per 
day whereas the highest BD exposure level of 90 ppm measured in the plant 
corresponds to smoking of about 22 cigarettes per day (43). Therefore, moderate 
smoking provides an important contribution to the amount of BD inhaled. The 
relationship of hemoglobin adducts (THB-Val) and smoking was studied by 
Begemann et al. (44) and Vacek et al. (45). Accordingly, mean THB-Val 
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concentrations were significantly higher in BD exposed smokers (567.5 pmol/g 
globin) than in BD exposed non-smokers (367.2 pmol/g globin). In addition, among 
unexposed males, smokers had a higher mean THB-Val concentration than did 
unexposed non-smokers (502 pmol/g globin versus 179 pmol/g globin). Therefore, 
smoking is identified an important source of BD-exposure and should be accounted 
for in human BD exposure assessment studies. 
 
5.5 Conclusion  
 The data presented clearly demonstrate the results of internal dose formation 
following 10 days exposure from low to high concentrations of BD in rodents. The 
application of the internal adduct dose equivalent provides valuable insights for cross 
species comparisons. Mice were shown to be more efficient in metabolism of BD to 
epoxides than rats, suggesting possible mechanisms responsible for the observed 
species differences in tumor susceptibility. Furthermore, the carcinogenic potency of 
BD between species can be quantitatively explained by this approach, using internal 
adduct doses combined with relative genotoxic potency, and a multiplicative risk 
model. The model provided estimation of tumor incidence data that are in reasonable 
agreement with observed numbers in long-term cancer bioassays. These data will be 
very helpful in science-based risk assessment. 
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Tables 
Table 5.1 Survival-adjusted neoplasm percentage for B6C3F1 mice and F344 rats in the long-term inhalation studies of 
1,3-Butadiene [NTP 1993 TR 434].  
Mice Exposure concentration (ppm) 
Sex Neoplastic lesion          Target organ  0 6.25 20 62.5 200      625 
Males       
                                                                                     
Initial number a 
 
Number of survivors 
 
- Malignant lymphomas                   All 
 
- Haemangiosarcoma                      Heart 
 
- Alveolar/bronchiolar carcinoma    Lung 
 
- Papilloma and carcinoma             Forestomach 
 
- Adenoma and adenocarcinoma   Harderian gland 
 
- Hepatocellular carcinoma             Liver 
 
Females       
                                                                                     
Initial number a 
 
Number of survivors 
 
-     Malignant lymphomas              All 
 
-     Haemangiosarcoma                Heart 
 
 
70 
 
35 
 
4 (9%)b 
 
0 (0%) 
 
22 (48%) 
 
1 (2%) 
 
6 (14%) 
 
31 (45%) 
 
 
 
70 
 
37 
 
10 (13%) 
 
0 (0%) 
 
 
70 
 
39 
 
3 (4%) 
 
0 (0%) 
 
23 (49%) 
 
0 (0%) 
 
7 (15%) 
 
27 (48%) 
 
 
 
70 
 
33 
 
14 (27%) 
 
0 (0%) 
 
 
70 
 
24 
 
8 (10%) 
 
1 (3%) 
 
20 (45%) 
 
0 (0%) 
 
11 (22%) 
 
35 (65%) 
 
 
 
70 
 
24 
 
18 (27%) 
 
0 (0%) 
 
 
70 
 
22 
 
11 (15%)c 
 
5 (14%)c 
 
33 (75%)c 
 
5 (3%) 
 
24 (51%)c 
 
32 (62%) 
 
 
 
70 
 
11 
 
10 (20%) 
 
1 (3%) 
 
 
70 
 
3 
 
9 (27%)c 
 
20 (64%)c 
 
42 (88%)c 
 
12 (29%)c 
 
33 (81%)c 
 
40 (86%) 
 
 
 
70 
 
0 
 
19 (40%)c 
 
20 (72%)c 
 
 
70 
 
0 
 
69 (97%)c 
 
6 (53%)c 
 
12 (45%)c 
 
13 (54%)c 
 
7 (64%)c 
 
12 (61%) 
 
 
 
70 
 
0 
 
43 (86%)c 
 
26 (83%)c 
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Mice Exposure concentration (ppm) 
Sex Neoplastic lesion          Target organ  0 6.25 20 62.5 200 625 
 
- Alveolar/bronchiolar carcinoma    Lung 
 
- Papilloma and carcinoma             Forestomach 
 
- Adenoma and adenocarcinoma   Harderian gland 
 
- Hepatocellular carcinoma             Liver 
 
- Adenocarcinoma                          Mammary gland 
 
- Benign and malignant                  Ovarian 
granulose cell 
 
4 (9%) 
 
0 (0%) 
 
9 (18%) 
 
17 (33%) 
 
0 (0%) 
 
1 (2%) 
 
15 (33%) 
 
0 (0%) 
 
10 (23%) 
 
20 (30%) 
 
2 (5%) 
 
0 (0%) 
 
19 (47%) 
 
3 (8%) 
 
7 (17%) 
 
23 (36%) 
 
2 (10%) 
 
2 (3%) 
 
27 (61%)c 
 
4 (6%) 
 
16 (41%) 
 
24 (51%)c 
 
6 (33%)c 
 
9 (26%)c 
 
32 (81%)c 
 
7 (23%)c 
 
22 (71%)c 
 
20 (65%)c 
 
13 (57%)c 
 
11 (44%)c 
 
25 (83%)c 
 
28 (83%)c 
 
7 (58%)c 
 
3 (22%) 
 
13 (67%)c 
 
6 (47%) 
 
Rats 
 
Exposure concentration (ppm) 
Sex Neoplastic lesion          Target organ  0 1,000 8,000 
Males       
                                                                                     
Initial number a 
 
Number of survivors 
 
- Exocrine adenoma                      Pancreas 
 
- Glial cell                                      Brain 
 
- Leydig cell tumor                        Testis 
 
 
 
110 
 
55 
 
3 (3%)b 
 
1 (1%) 
 
0 (0%) 
 
 
110 
 
50 
 
1(1%) 
 
4 (4%) 
 
3 (3%) 
 
 
110 
 
69 
 
10 (10%) 
 
5 (5%) 
 
8 (8%)c 
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Rats 
 
Exposure concentration (ppm) 
Sex Neoplastic lesion          Target organ  0 1,000 8,000 
 
Females 
 
Initial number a 
 
Number of survivors 
 
• Sarcoma                                  Uterus 
 
• Follicular cell adenoma           Thyroid gland 
 
• Benign or malignant                Mammary gland 
 
• Carcinoma                              Zymbal gland 
 
 
 
 
110 
 
60 
 
1 (1%) 
 
0 (0%) 
 
50 (50%) 
 
0 (0%) 
 
 
 
110 
 
68 
 
4 (4%) 
 
2 (2%) 
 
79 (79%) 
 
0 (0%) 
 
 
 
110 
 
76 
 
5 (5%) 
 
10 (10%)c 
 
81 (81%)c 
 
4 (4%) 
From  Melnick et al (1990); National Toxicology Program (1993); Owen (1987); Owen (1993) 
aInitial numbers include animals removed from study for interim sacrifies. 
bMortality-adjusted tumor rates are given in parentheses. 
cp < 0.05, based on regression analysis with adjustment for intercurrent mortality. 
 
 
 
 
161 
 
 
Table 5.2 Hemoglobin adducts from rats and mice exposed to 1,3-Butadiene 
for 10 days 
 
38 ± 5
19 ± 5
142 ± 17
260 ± 15
2324 ± 212
4383 ± 373
35 ± 8
15 ± 8
152 ± 43
352 ± 34
525 ± 160
1008 ± 235
1448 ± 445
2587 ± 238
4490 ± 467
34 ± 4
1.1 ± 0.2
70 ± 3
585 ± 7
796 ± 84
36 ± 4
2.4 ± 0.3
29 ± 3
59 ± 6
220 ± 19
481 ± 53
606 ± 75
737 ± 74
[pmol/g]
EB-diolDEBEBBD 
exposure
Species/
Duration
Adduct/ppm
BD
Adduct/ppm
BD
[pmol/g]Adduct/ppm
BD
[pmol/g][ppm]
190
284
173
12
7
ND
30
30
33
4
3
ND
3.0 ± 1.0
15 ± 2
50 ± 9
859 ± 126
1980 ± 195
ND
23
22
21
6
6
ND
2.3 ± 0.5
11 ± 1
32 ± 3
1165 ± 112
3644 ± 520
0
0.1
0.5
1.5
200
625
10 days
Male Mice 
(B6C3F1)
150
304
352
350
161
23
13
7
ND
21
22
20
25
12
7
4
2
ND
2.1 ± 1.4
11 ± 3
20 ± 2
38 ± 2
76 ± 10
419 ± 63
859 ± 62
1532 ± 170
242
23
22
16
20
9
6
4
6
ND
2.3 ± 0.8
11 ± 1
16 ± 1.2
30 ± 5
59 ± 9
364 ± 55
751 ± 23
3644 ± 534
0
0.1
0.5
1
1.5
6.25
62.5
200
625
10 days
Female 
Mice 
(B6C3F1)
2.2
46
3.0
1.3
ND
1.4
1.3
0.6
0.2
ND
0.7 ± 0.2
2.0 ± 0.4
120 ± 11
117 ± 12
ND
1.8
1.5
0.9
0.6
ND
0.8 ± 0.1
2.3 ± 0.4
171 ± 0.4
394 ± 8
0
0.5
1.5
200
625
10 days
Male Rats 
(F344)
4.8
29
39
35
7.7
3.0
1.2
ND
1.8
1.4
1.3
1.1
0.8
0.6
0.2
ND
0.8 ± 0.1
1.4 ± 0.2
2.0 ± 0.5
6.7 ± 0.7
47 ± 8
123 ± 8
124 ± 11
ND
1.8
1.6
1.7
1.3
1
0.7
0.7
ND
0.9 ± 0.1
1.6 ± 0.5
2.5 ± 0.4
8.1 ± 0.7
60 ± 3
148 ± 19
410 ± 15
0
0.5
1
1.5
6.25
62.5
200
625
10 days
Female 
Rats (F344)
 
Endogenous THB-Val was substracted in all group using data from control animal; 36 pmol/g 
globin in female rats, 34 pmol/g globin in male rats, 35 pmol/g globin in female mice and 38 
pmol/g globin in male mice 
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Table 5.3 Internal adduct dose and EB dose equivalent from rats and mice 
exposed to 1,3-Butadiene for 10 days 
1158
1240
205
104
225
137
9
6
11
12
2
1
13
12
3
3
30
90
12000
37500
0.5
1.5
200
625
10 days
Male Mice 
(B6C3F1)
1060
765
967
431
207
204
105
242
280
278
128
18
10
7
10
7
9
4
2
2
1
12
9
11
5
3
2
3
30
60
90
375 
3750
12000
37500
0.5
1
1.5
6.25
62.5
200
625
10 days
Female Mice 
(B6C3F1)
47
43
13
6
3.0
20.0
2.2
0.9
0.42
0.40
0.12
0.06
0.67
0.63
0.25
0.23
30
90
12000
37500
0.5
1.5
200
625
10 days
Male Rats 
(F344)
49
47
46
38
30
19
6
3.5
21.2
28.3
26.7
5.6
2.2
0.9
0.48
0.42
0.40
0.32
0.29
0.18
0.06
0.73
0.67
0.64
0.54
0.31
0.25
0.27
30
60
90
375 
3750
12000
37500
0.5
1
1.5
6.25
62.5
200
625
10 days
Female Rats 
(F344)
DEB-equi.EB-diolDEBEBppmhppm
Internal adduct dose [mMh/ppmh]BD exposureSpecies/
Duration
 
Endogenous THB-Val was substracted from EB-diol prior to calculating EB dose equivalent. 
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Figures 
 
 
 
Figure 5.1 BD metabolism and formation of N-terminal valine adducts 
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Figure 5.2 Exposure-response of HB-Val in female B6C3F1 mice and F344 
rats 
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Figure 5.3 Exposure-response of pyr-Val in female B6C3F1 mice and F344 
rats 
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Figure 5.4 Exposure-response of THB-Val in female B6C3F1 mice and F344 
rats 
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Figure 5.5 Gender differences in F344 rats (a) and B6C3F1 mice (b) exposed 
to BD for 10 days 
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Figure 5.6 Exposure-response curves of EB dose equivalent  
(blue curve) versus BD mutagenic efficiency (induced Hprt mutant frequency/ppm 
BD × 100; green line) in female B6C3F1 mice exposed for 10 days to BD 
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Figure 5.7  EB dose equivalent (mMh/ppmh) versus BD mutagenic 
efficiency(induced Hprt mutant frequency/ppm BD × 100) in female B6C3F1 mice 
exposed for 10 days to BD 
 
 
 
 
 
 
 
 
 
170 
 
 
 
 
Figure 5.8 The percentage of predicted versus observed tumor incidence in 
mice from multiplicative cancer risk model 
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Figure 5.9 The estimated percentage of tumor incidence in male mice at 
different BD exposure levels 
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Figure 5.10 The estimated percentage of tumor incidence in female mice at 
different BD exposure levels 
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CHAPTER VI 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
6.1 Conclusions 
1,3-Butadiene (BD) is a known animal and human carcinogen (1, 2). BD 
inhalation cancer bioassays demonstrated striking interspecies and gender 
differences, where mice were much more susceptible to tumor formation than 
rats, complicating human risk assessment (3, 4). A gender difference in 
susceptibility was also demonstrated in mice, with female mice developing tumors 
at lower exposures than males. To date, the complexity of BD carcinogenesis 
largely has been attributed to species-dependent differences in metabolic 
activation of BD to reactive electrophilic metabolites (5). Species and gender 
differences related to BD metabolism can be examined by measuring suitable 
biomarkers. Hemoglobin adducts have been widely used as surrogate biomarkers 
for exposure. Measurement of globin adducts provides useful information on 
exposure-specific internal formation of individual epoxide metabolites. In addition, 
gender differences in mutation induction and DNA repair may further expand 
important differences between exposed male and female rats and mice.   
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In this dissertation, we have investigated the internal adduct dose of the 
individual epoxides to assign the relative risk for each metabolite and to improve 
our understanding on the molecular mechanisms responsible for major species 
differences in BD carcinogenicity. This dissertation is presented in four related 
chapters (Chapters 2-5).  Each chapter contains research that makes significant 
contributions to improving BD exposure and risk assessment.   
In chapter 2, we described the methodology for synthesis and 
characterization of epoxide alkylated peptides to serve as analyte and internal 
standards for globin adduct quantification in rodents exposed to BD. To 
synthesize the standard peptides, (1-11) globin peptides specific for rat and 
mouse were reacted with butadiene monoepoxides (EB and EB-diol) using a 
direct alkylation method. The peptides were purified by HPLC and characterized 
by their fragmentation patterns obtained from tandem mass spectrometry 
(MS/MS). Use of isotope labeled [13C15N5] amino acids on N-terminal valine in the 
oligopeptide synthesis provided the required isotopic labeled peptide for use as 
an internal standard. This strategy enabled us to obtain pure and well 
characterized alkylated analyte standard peptides in adequate quantity for 
quantification of globin adducts in rodent samples exposed to BD.  
In chapter 3, we developed a standard peptide quantitation method based 
on the analysis of their amino acid components after acid hydrolysis, using ultra 
performance LC-MS/MS (UPLC-MS/MS). Accurate quantitation of the standard 
peptides was challenging because the amounts of standard peptides available 
are usually so small that accurate weights cannot be obtained. Additionally, 
peptides are hygroscopic and easily absorb moisture from the air, and the 
presence of water and salts leads to overestimation of peptide amounts. To 
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overcome these limitations, this approach accurately quantitates micromolar 
solutions of standard peptides, significantly reduces the amounts needed and 
allows for high throughput quantitative analysis of peptide standards.  
In chapter 4, we have developed a simultaneous analysis of all three 
adducts formed by BD epoxides at the N-terminal valine of globin alpha chain in 
female F344 rats exposed to 1,3-butadiene via inhalation. Our laboratory has 
previously developed quantitative immunoaffinity (IA) LC-ESI+-MS/MS method for 
two adducts of EB-specific adduct, HB-Val, and DEB-specific adduct, pyr-Val. 
Recently, the method has been applied with UPLC-ESI+-MS/MS. This method 
allow the measurement of adducts over a wide range of samples from BD 
exposed mice and rats. However, the application of the method is labor intensive 
requiring extensive sample processing time since the analysis of all three adducts 
could not be measured in a single run. Therefore, a simultaneous analysis of all 
three adducts in a single run represents a great advance in the analysis of N-
terminal globin adducts. In this study, IA columns were produced that combined 
all three antibodies raised against the alkylated standard peptides for sample 
purification. The sample incubation period had to be adjusted from 1 h to 4 h in 
order to obtain acceptable recoveries of the method. The improved quantitation 
method was highly sensitive, accurate, and selective for all three BD adducts, 
allowing the detection of low amounts of adducts in 50 mg globin in rats from 
exposure as low as 0.5 ppm BD.  
We further applied this method to generate a comprehensive dose 
response for BD reactive epoxide in female rats exposed to BD. F344 rats were 
exposed by inhalation to various concentrations of BD ranging form 0.1 to 625 
ppm. The control animals did not contain detectable amounts of HB-Val and pyr-
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Val. In contrast, THB-Val (36.8 ± 3.9 pmol/g globin) has been detected in control 
female rats with no exogenous BD exposure as a result of endogenous THB-Val 
formation. The formation of BD-epoxide adducts increased with increasing 
exposures. It was most efficient with regards to formation per ppm BD at low 
exposures. The amounts of pyr-Val and THB-Val formation saturated at 
exposures greater than 200 ppm for 10 days. In contrast, HB-Val linearly 
increased with exposure. The data reported herein, demonstrated for the first time 
the formation of all three BD-epoxide globin adducts in female F344 rats. These 
data will be very helpful for understanding the mechanisms of BD carcinogenesis 
and mutagenicity. 
After our extensive work on method development of all three BD derived 
epoxides globin adduct, in chapter 5, we applied the improved method to analyze 
globin samples from both genders of rats and mice exposed to BD. The number 
of globin adducts were then converted into EB dose equivalents. These were 
calculated on the basis of the combined internal dose (globin adducts) and the 
relative genotoxic potency of the respective epoxides inferred from the efficiency 
of inducing mutations at the Hprt locus. Then, the multiplicative cancer risk model 
was applied to quantitatively estimate tumor incidence using the EB dose 
equivalent and long-term cancer bioassay data. The evaluation of the cancer data 
for BD is a challenge because of large species differences in sensitivity, and 
because all three epoxide metabolites are genotoxic and may contribute to 
carcinogenesis. 
Based on the EB equivalent, higher exposures formed lower amounts per 
ppm BD. This indicates that metabolism of BD to epoxides is most effective at low 
exposures. The EB equivalent for mice was about 40-fold higher than that of rats 
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at similar exposures. No gender differences were noted in globin adducts of mice 
or rats at all exposures. The application of internal dose equivalents has the 
potential to provide valuable insight for cross species comparisons. Mice were 
shown to be more efficient in metabolism of BD to epoxides than rats, 
demonstrating important mechanisms responsible for the observed species 
differences in tumor susceptibility. The tumor incidences predicted with the 
multiplicative cancer risk model correlated well with the earlier observed tumor 
incidences in cancer bioassays. As such, internal dose equivalents provide 
quantitative data on biomarkers of exposure that can extend the scientific basis 
for improved risk assessment. 
 
6.2 Future directions 
 As mention earlier, we have generated data to address critical species 
differences in BD metabolism and carcinogenesis. The results, we believe 
substantially improve our ability to conduct BD risk assessments.  However, there 
are still some critical issues to be further investigated, which will bridge the 
current gaps of our understanding on BD.   
Our study has focused on the quantitative analysis of globin adducts in 
rodent samples exposed to BD. However, BD metabolism and globin adduct 
formation in humans remains to be fully elucidated. Presently, We have 
conducted extensive exposure-biomarker studies on mice, rats and humans (6). 
Using low exposures that range from current occupational levels to human 
exposures from tobacco smoke has provided evidence that mice are very 
different from humans, with mice forming ~200 times more DEB than humans at 
exposures to 0.1-1.5 ppm BD (6). The studies utilized Edman chemistry, followed 
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by GC-MS analysis for HB-Val and THB-Val and IA UPLC-MS for pyr-Val. 
Therefore, we are simultaneously quantifying all three BD epoxide globin adducts 
in workers exposed to BD by using improved IA-UPLC-MS/MS method. We 
expect to generate extensive exposure-response data valuable insight for cross-
species comparisons at low exposures and present the most comprehensive data 
set available for the three species.  
Additional research will be necessary to identify the mechanism(s) 
responsible for gender differences in mutagenesis and cancer sensitivity. The 
globin data demonstrated that there were no gender differences in metabolism 
[(7) and data in Chapter 5], yet female rats and mice have been shown to have 
increased amounts of DNA cross-links and Hprt mutations. The collective data 
strongly suggests that a deficiency in DNA cross-link repair in females is the most 
plausible hypothesis for the gender differences in mutagenic and carcinogenic 
susceptibility. In addition, unpublished preliminary results from our laboratory 
demonstrate that homologous recombination and nucleotide excision repair are 
critical pathways for DEB. Therefore, more studies are needed in order to develop 
data based on gender differences in repair of DNA cross-links. This can be 
accomplished by exposing both genders of BRCA1 -/- mice and wild-type mice to 
DEB and measuring the bis-N7G-BD adducts in tissues over different periods of 
time post exposure using HPLC-MS/MS method. Such studies are clearly 
required to establish gender differences in DNA repair pathway. It will also be 
critical to determine if these gender differences are present in humans, as that 
would suggest greater susceptibility of females in humans exposed to BD and 
possible to many other bifunctional chemicals, including many cancer 
chemotherapeutics. 
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